CA2309881A1 - Use of nadph oxidase inhibitors for the manufacture of a medicament for prevention of atherosclerosis - Google Patents
Use of nadph oxidase inhibitors for the manufacture of a medicament for prevention of atherosclerosis Download PDFInfo
- Publication number
- CA2309881A1 CA2309881A1 CA002309881A CA2309881A CA2309881A1 CA 2309881 A1 CA2309881 A1 CA 2309881A1 CA 002309881 A CA002309881 A CA 002309881A CA 2309881 A CA2309881 A CA 2309881A CA 2309881 A1 CA2309881 A1 CA 2309881A1
- Authority
- CA
- Canada
- Prior art keywords
- nadph oxidase
- apocynin
- atherosclerosis
- ldl
- endocytosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000004722 NADPH Oxidases Human genes 0.000 title claims abstract description 76
- 108010002998 NADPH Oxidases Proteins 0.000 title claims abstract description 76
- 201000001320 Atherosclerosis Diseases 0.000 title claims abstract description 41
- 239000003112 inhibitor Substances 0.000 title abstract description 18
- 238000004519 manufacturing process Methods 0.000 title abstract description 12
- 230000002265 prevention Effects 0.000 title abstract description 9
- 239000003814 drug Substances 0.000 title description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 36
- 201000010099 disease Diseases 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 25
- 230000000694 effects Effects 0.000 claims description 37
- 230000003511 endothelial effect Effects 0.000 claims description 18
- 210000000224 granular leucocyte Anatomy 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 238000000684 flow cytometry Methods 0.000 claims description 3
- 230000012202 endocytosis Effects 0.000 abstract description 35
- 239000003642 reactive oxygen metabolite Substances 0.000 abstract description 28
- 229940123857 NADPH oxidase inhibitor Drugs 0.000 abstract description 24
- 230000002792 vascular Effects 0.000 abstract description 18
- 230000000923 atherogenic effect Effects 0.000 abstract description 5
- 241000124008 Mammalia Species 0.000 abstract description 4
- 238000002405 diagnostic procedure Methods 0.000 abstract description 3
- 230000003247 decreasing effect Effects 0.000 abstract description 2
- DFYRUELUNQRZTB-UHFFFAOYSA-N apocynin Chemical compound COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 description 154
- 229930188866 apocynin Natural products 0.000 description 73
- 210000002889 endothelial cell Anatomy 0.000 description 64
- 108010007622 LDL Lipoproteins Proteins 0.000 description 38
- 102000007330 LDL Lipoproteins Human genes 0.000 description 38
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 38
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 31
- 241000283973 Oryctolagus cuniculus Species 0.000 description 22
- 238000001994 activation Methods 0.000 description 22
- 230000004913 activation Effects 0.000 description 21
- 229940114079 arachidonic acid Drugs 0.000 description 19
- 235000021342 arachidonic acid Nutrition 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 125000000217 alkyl group Chemical group 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 230000003143 atherosclerotic effect Effects 0.000 description 16
- -1 cyclopropylethyl Chemical group 0.000 description 15
- 239000012528 membrane Substances 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 235000012000 cholesterol Nutrition 0.000 description 12
- 230000000260 hypercholesteremic effect Effects 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 125000000753 cycloalkyl group Chemical group 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 210000000709 aorta Anatomy 0.000 description 10
- 230000001413 cellular effect Effects 0.000 description 10
- 125000001072 heteroaryl group Chemical group 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 9
- 125000003342 alkenyl group Chemical group 0.000 description 9
- 125000000304 alkynyl group Chemical group 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 230000001086 cytosolic effect Effects 0.000 description 8
- 239000000539 dimer Substances 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 238000008214 LDL Cholesterol Methods 0.000 description 7
- 231100000517 death Toxicity 0.000 description 7
- 210000003038 endothelium Anatomy 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 102000004316 Oxidoreductases Human genes 0.000 description 6
- 108090000854 Oxidoreductases Proteins 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 108010028554 LDL Cholesterol Proteins 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 230000001159 endocytotic effect Effects 0.000 description 5
- 125000005553 heteroaryloxy group Chemical group 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000004941 influx Effects 0.000 description 5
- 210000001589 microsome Anatomy 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- FKJSFKCZZIXQIP-UHFFFAOYSA-N 2-bromo-1-(4-bromophenyl)ethanone Chemical compound BrCC(=O)C1=CC=C(Br)C=C1 FKJSFKCZZIXQIP-UHFFFAOYSA-N 0.000 description 4
- 101001022794 Homo sapiens Flavin-containing monooxygenase 5 Proteins 0.000 description 4
- 210000000702 aorta abdominal Anatomy 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000019254 respiratory burst Effects 0.000 description 4
- 238000002390 rotary evaporation Methods 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- KJTLQQUUPVSXIM-ZCFIWIBFSA-N (R)-mevalonic acid Chemical compound OCC[C@](O)(C)CC(O)=O KJTLQQUUPVSXIM-ZCFIWIBFSA-N 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 101150041968 CDC13 gene Proteins 0.000 description 3
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 description 3
- 108010052832 Cytochromes Proteins 0.000 description 3
- 102000018832 Cytochromes Human genes 0.000 description 3
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 3
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 3
- 208000018262 Peripheral vascular disease Diseases 0.000 description 3
- 102000015439 Phospholipases Human genes 0.000 description 3
- 108010064785 Phospholipases Proteins 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 125000004442 acylamino group Chemical group 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 208000016532 chronic granulomatous disease Diseases 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 229960004844 lovastatin Drugs 0.000 description 3
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 3
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 125000000547 substituted alkyl group Chemical group 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 238000011179 visual inspection Methods 0.000 description 3
- IBXNCJKFFQIKKY-UHFFFAOYSA-N 1-pentyne Chemical compound CCCC#C IBXNCJKFFQIKKY-UHFFFAOYSA-N 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 101000988577 Homo sapiens 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 241001470703 Picrorhiza kurrooa Species 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- KDKYADYSIPSCCQ-UHFFFAOYSA-N but-1-yne Chemical compound CCC#C KDKYADYSIPSCCQ-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- 230000027721 electron transport chain Effects 0.000 description 2
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 2
- 238000001506 fluorescence spectroscopy Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000006122 isoprenylation Effects 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 208000023516 stroke disease Diseases 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000031998 transcytosis Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 229940035936 ubiquinone Drugs 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical group C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- VQVUBYASAICPFU-UHFFFAOYSA-N (6'-acetyloxy-2',7'-dichloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(OC(C)=O)C=C1OC1=C2C=C(Cl)C(OC(=O)C)=C1 VQVUBYASAICPFU-UHFFFAOYSA-N 0.000 description 1
- 150000005206 1,2-dihydroxybenzenes Chemical class 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- VFNKZQNIXUFLBC-UHFFFAOYSA-N 2',7'-dichlorofluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(O)C=C1OC1=C2C=C(Cl)C(O)=C1 VFNKZQNIXUFLBC-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- XNCSCQSQSGDGES-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]propyl-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(O)=O XNCSCQSQSGDGES-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000006029 2-methyl-2-butenyl group Chemical group 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- PPWNCLVNXGCGAF-UHFFFAOYSA-N 3,3-dimethylbut-1-yne Chemical compound CC(C)(C)C#C PPWNCLVNXGCGAF-UHFFFAOYSA-N 0.000 description 1
- USCSRAJGJYMJFZ-UHFFFAOYSA-N 3-methyl-1-butyne Chemical compound CC(C)C#C USCSRAJGJYMJFZ-UHFFFAOYSA-N 0.000 description 1
- 125000006618 5- to 10-membered aromatic heterocyclic group Chemical group 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000006418 Brown reaction Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- VGMFHMLQOYWYHN-UHFFFAOYSA-N Compactin Natural products OCC1OC(OC2C(O)C(O)C(CO)OC2Oc3cc(O)c4C(=O)C(=COc4c3)c5ccc(O)c(O)c5)C(O)C(O)C1O VGMFHMLQOYWYHN-UHFFFAOYSA-N 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 102100025287 Cytochrome b Human genes 0.000 description 1
- 108010075028 Cytochromes b Proteins 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010014476 Elevated cholesterol Diseases 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 238000005863 Friedel-Crafts acylation reaction Methods 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 101150051715 Phax gene Proteins 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 102100026918 Phospholipase A2 Human genes 0.000 description 1
- 101710096328 Phospholipase A2 Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010047112 Vasculitides Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000005518 carboxamido group Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960000559 dextrothyroxine sodium Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- QLBHNVFOQLIYTH-UHFFFAOYSA-L dipotassium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [K+].[K+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O QLBHNVFOQLIYTH-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229930003811 natural phenol Natural products 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- YCIMNLLNPGFGHC-UHFFFAOYSA-N o-dihydroxy-benzene Natural products OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000006025 oxidative dimerization reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical compound CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000006513 pyridinyl methyl group Chemical group 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A method for the prevention and treatment of atherosclerosis and its related diseases in mammals, in which an NADPH oxidase inhibitor is administered, is provided. The NADPH oxidase inhibitor prevents the production of reactive oxygen species upon exposure of endothetial cells to atherogenic LDL levels, thus resulting in decreased endocytosis and vascular hyperpermeability. Preferred NADPH oxidase inhibitors are of formula (I). Additionally, there is provided a diagnostic method for predicting risk of a human patient to atherosclerosis-related diseases.
Description
USE OF NADPH OXIDASE iNNIBfPORS FOR THE MANUFACTURE OF A MEDICAMENT FOR
PREVENTION OF ATHEROSCLEROSIS
Statement As To Rights Under Federally Sponsored Research S This invention was made with support from the Department of Veterans Affairs (Merit Review 0002) and from the National Institutes of Health (Grant No.
5801 HL49573). The United States government may have certain rights in the invention.
Field of the Invention The present invention relates to therapeutic methods for the prevention and treatment of atherosclerosis and diseases resulting from endothelial hyperpermeability. More particularly, the present invention relates to the prevention and treatment of these diseases through the administration of an NADPH oxidase inhibitor.
Background of the Invention Atherosclerosis with its sequelae of heart attack, strokes, and peripheral vascular disease is the leading cause of death in the United States with over 800,000 deaths per year. Excluding accidents, suicides, and homicides, atherosclerotic-related diseases account for nearly 50% of all deaths.
Epidemiologic studies show that a large percentage of - those afflicted have an elevation in blood low density lipoprotein (LDL) levels. LDL carries cholesterol from the liver to body tissues. An elevated cholesterol level (hypercholesterolemia) is commonly associated with an elevation in LDL levels.
PREVENTION OF ATHEROSCLEROSIS
Statement As To Rights Under Federally Sponsored Research S This invention was made with support from the Department of Veterans Affairs (Merit Review 0002) and from the National Institutes of Health (Grant No.
5801 HL49573). The United States government may have certain rights in the invention.
Field of the Invention The present invention relates to therapeutic methods for the prevention and treatment of atherosclerosis and diseases resulting from endothelial hyperpermeability. More particularly, the present invention relates to the prevention and treatment of these diseases through the administration of an NADPH oxidase inhibitor.
Background of the Invention Atherosclerosis with its sequelae of heart attack, strokes, and peripheral vascular disease is the leading cause of death in the United States with over 800,000 deaths per year. Excluding accidents, suicides, and homicides, atherosclerotic-related diseases account for nearly 50% of all deaths.
Epidemiologic studies show that a large percentage of - those afflicted have an elevation in blood low density lipoprotein (LDL) levels. LDL carries cholesterol from the liver to body tissues. An elevated cholesterol level (hypercholesterolemia) is commonly associated with an elevation in LDL levels.
High blood cholesterol levels, specifically LDL-cholesterol, increase risk for coronary heart disease (CHD), whereas lowering total cholesterol and LDL-cholesterol levels reduces CHD risk.
Many pharmaceutical agents have been developed to treat or prevent atherosclerosis and its complications by controlling abnormally high blood LDL levels or lowering cholesterol levels. The most widely known of these agents include nicotinic acid, clofibrate; dextrothyroxine sodium, neomycin, beta-sitosterol, probucol, cholestyramine and HMG-CoA
reductase inhibitors, such as lovastatin and simvastatin. However, the usefulness of these agents is limited by the frequent occurrence of acute side effects. Such side effects may include intense cutaneous flush, pruritus, gastrointestinal irritation, hepatotoxicity, cardiac arrhythmias, nausea, weight gain, alopecia, impotence, abdominal pain, diarrhea, eosinophilia, skin rash, musculoskeletal pain, blurred vision, mild anemia, ,_ leukopenia, the enhancement of gallstones, constipation, and impaction. Moreover, there is only a partial correlation between lowering of serum cholesterol and the reduction of atherosclerosis.
Not all patients with atherosclerotic disease have high cholesterol and not all patients with high cholesterol have atherosclerotic disease.
The pathobiology of atherosclerosis indicates a major role for vascular endothelial involvement. ' Perturbation of the endothelium, without overt death and loss of endothelial cells, with resultant change in endothelial permeability to various blood materials is an important feature in the development of atherosclerotic lesions. Materials contained in the blood subsequently pass through this endothelial tissue and accumulate in the intima of the arterial wall. Even a moderate increase in endothelial permeability (hyperpermeability) is accompanied by a significant increase in the incidence of atherosclerotic events.
One mechanism by which vascular hyperpermeability can occur in the presence of an intact endothelium is increased endothelial endocytosis due to perturbation of the endothelium. The endothelium can be perturbed by various conditions, including high levels of low density lipoprotein (LDL) in the bloodstream and shear stress, as occurs in hypertension. Diabetes mellitus and smoking can also give rise to perturbation of the endothelium. I have conducted studies in which human vascular endothelial cells (EC) were exposed to high LDL concentrations (up to 330 mg/dL cholesterol) for prolonged periods. The 2o results, as demonstrated by stability of cell count for instance, indicate that EC death and loss do not occur in humans during the promotion of atherosclerotic plaque formation by LDL.
Initially, endothelial perturbation occurs, resulting in increased endocytosis and LDL
accumulation in the subendothelial space. Thus, exposure to high LDL levels induces heightened EC
endocytosis. Studies indicate that exposure to LDL, in concentration ranges that are considered from epidemiologic studies to be atherogenic (endothelial cells exposed to >140 mg/dL LDL cholesterol, for example), is necessary for exaggerated endocytosis.
Another key finding is that once heightened endocytosis develops, it persists. Such a persistent change in EC functional state is consistent with the endothelial perturbation, or vascular hyperpermeability, concept.
Endocytosis is a fundamental, apparently ubiquitous, cellular event. During endocytosis, a segment of plasma membrane is interiorized to form a vesicle that migrates into the cytoplasm. This vesicle may participate in transcellular transport via transcytosis. The endocytosis regulatory mechanism is not well understood, but my studies demonstrate that reactive oxygen species, such~as HZOZ
and OZ-, modulate heightened EC endocytosis. Cells generate reactive oxygen species (ROS) as byproducts of normal cellular metabolism. Perturbed endothelial cells increase reactive oxygen species production via the activation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase.
NADPH oxidase is an enzyme that has been well characterized in leukocytes, but leukocyte-type NADPH
oxidase has not been previously identified in endothelial cells. I have demonstrated that it occurs in endothelial cells. Activation of NADPH
oxidase results in the transfer of electrons from NADPH to oxygen, resulting in the generation of reactive oxygen species (ROS) such as OZ- and Hz02.
The active form of the oxidase is a complex assembled from membrane-bound proteins that include cytochrome bsse ( Composed of gp91 ~Phox~ and p22 ~phox] ) and cytosolic components, of which three have been characterized, P4~ (phoxl ~ P67 [phox] and a low molecular weight GTP-binding protein. Cytochrome b55a consists of a 22 kD
polypeptide which tightly binds to a glycosylated 91 _5_ kD polypeptide. The glycosylated 91 kD polypeptide is an integral membrane protein that serves to anchor the 22 kD polypeptide.
It is known that inheritable abnormalities of the NADPH oxidase enzyme complex result in Chronic Granulomatous Disease (CGD), a congenital disorder in which leukocytes are unable to generate reactive oxygen species in response to microorganisms.
Studies on CGD, in which NADPH oxidase activity is insufficient or absent, have shown that genetic variants of NADPH oxidase exist. There have been no studies, though, to identify NADPH oxidase genetic variants that produce excessive amounts of reactive oxygen species. If such variants exist and are common in our population, then people inheriting these genetic variants may be at higher risk of heart attack, stroke, and peripheral vascular disease.
The membrane-bound enzyme, NADPH oxidase, exists in an inactive form in quiescent cells. Upon cell perturbation, the enzyme complex assembles and is converted into an active state causing intensified reactive oxygen species generation (oxidative burst).
Studies attempting to delineate the NADPH oxidase activation mechanism indicate that unsaturated fatty acids, most potently arachidonic acid, directly activate NADPH oxidase. To ascertain if arachidonic acid activates the NADPH oxidase found in endothelial cells, studies were carried out in which cells were directly exposed to increasing arachidonic acid concentrations and reactive oxygen species production was measured. For these studies, EC were incubated with 1 to 25 ~cM arachidonic acid and H20z production measured. It was shown that arachidonic acid both induces EC HZOZ generation and promotes heightened EC
endocytosis.
One explanation for the correlation between high LDL and atherosclerosis based on the above S information is that exposure to high levels of LDL~s promote phospholipase AZ activation. At an intracellular threshold level, cytosolic free arachidonic acid converts NADPH oxidase from a dormant to an active state.
Evidence from my experiments indicates that reactive oxygen species modulate heightened '' endocytosis, a characteristic of atherosclerosis, and that NADPH oxidase is the major cellular source.
Although NADPH oxidase inhibitors are claimed to be effective in treating inflammatory conditions, they have not been heretofore suggested to treat diseases such as atherosclerosis, whose initial phase is characterized by increased endocytosis and vascular hyperpermeability. For example, European patent application 551662 discloses the use of NADPH oxidase inhibitors to control acute and chronic inflammations of the airways, joints, and blood vessels. Such inflammations of the vessels include those arterioscleroses that are of inflammatory origin, but the EP application does not envision atherosclerosis, because atherosclerosis is initiated by a metabolic condition, not by inflammation.
The use of 4-hydroxy-3-methoxyacetophenone v (trivial name, apocynin) as an NADPH oxidase inhibitor is known, and it has been suggested to be ', of utility in treating inflammatory diseases.
Apocynin is a natural phenol isolated from the root of the plant Picrorhiza kurroa, which grows in the Himalaya mountains. Extracts of Picrorhiza kurroa have been used in traditional medicine in Southeast Asia for the treatment of diseases connected with inflammation and for the treatment of a variety of conditions including liver and lung diseases, fever, skin lesions, worm infections, rheumatic disease, urinary disorders, heart failure, and snake and scorpion bites. A more recent reference [Engels et al. FEBS Lett., 305, 254-56 (1992)] suggests that apocynin_may also be useful in preventing thrombosis.
However, neither apocynin nor any other NADPH oxidase inhibitor has been shown to prevent atherosclerosis or vascular hyperpermeability attributable to heightened EC endocytosis and high LDL
concentrations.
A method that prevents and treats atherosclerosis and its associated diseases, that is effective in most patients, and that avoids patient-deterring side effects would represent a substantial advance toward eliminating a major cause of death in this country. A method employing a readily available medicament that has already been used in humans would present additional significant advantages in the prevention and treatment of atherosclerosis and related diseases. In addition, a diagnostic method for predicting an individual's potential risk of developing atherosclerosis is highly desirable.
Summarv of the Invention The present invention relates to the surprising discovery of an effective method and composition for treating and preventing atherosclerosis in mammals.
The present invention provides a method for the therapeutic use of an NADPH oxidase inhibitor, preferably apocynin, for the treatment and prevention of conditions resulting from endothelial hyperpermeability, such as atherosclerosis.
Inhibition of NADPH oxidase activation in endothelial cells diminishes vascular hyperpermeability. Other conditions associated with vascular hyperpermeability can also be treated or prevented by administering an NADPH oxidase inhibitor such as apocynin.
In one aspect, the present invention relates to methods for preventing or treating a condition ' resulting from endothelial hyperpermeability. The method comprises administering to a mammal suffering from a condition resulting from endothelial hyperpermeability a therapeutically effective amount of an NADPH oxidase inhibitor or a metabolic precursor to an NADPH oxidase inhibitor. The NADPH
oxidase inhibition that results from the method of the invention may be distinguished by several overla in but distinct, features: (1) the dose of PP g, NADPH oxidase inhibitor or precursor may be insufficient to lower serum LDL by more than 10%; (2) the NADPH oxidase inhibitor or precursor may have a lower ICSQ vs human NADPH oxidase than vs human HMG-CoA reductase; or (3) the NADPH oxidase inhibitor or precursor may effect statistically equivalent inhibition of human NADPH oxidase in the presence and absence of mevalonate.
In another aspect, the invention relates to a method of treating or preventing a condition resulting from endothelial hyper-permeability which comprises administering to a mammal a therapeutically effective amount of a substance which inhibits p47~phax]
translocation to the gp91 ~phoX~ and p22 ~phoX~ membrane bound NADPH oxidase components.
In a preferred aspect of the invention, the NADPH oxidase inhibitor is a compound of the formula:
R
R' _~ hl oR' I
whereu'n R1, R2 and R' are independently chosen from the group consisting of H, alkyl, cycloalkyl, heterocycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl and substituted alkyl, cycloalkyl, heterocycloalkyl, alkenyl and alkynyl.
In another preferred aspect of the invention, the NADPH oxidase inhibitor is of the formula:
R .1 ~ O H
R ~(~)I . ~~ ~~ .<I.0 O
a 0 OH1':Iw'R~ O O~~~.1.'R~
II III
or a tautomer thereof , wherein R1, RZ and R' are independently chosen from the group consisting of H, alkyl, cycloalkyl, heterocycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl and substituted alkyl, cycloalkyl, heterocycloalkyl, alkenyl and alkynyl.
In a more preferred aspect of the invention, the NADPH oxidase inhibitor is of the formula I, II or I I I , wherein R1 and Rz are each methyl and R' is H .
Compounds of the formula I are widely available commercially. Those that are not commercially available can be conveniently prepared by Friedel-Crafts acylation of the appropriate phenol or protected phenol, by aryllithium addition of a protected phenol to the appropriate carboxylic acid or arylcadmium addition to an acid chloride, followed by deprotection, as well as by any of the other well-known methods for forming ketones.
Other-compounds of the genus II may be made in analogous fashion by oxidative dimerization of the appropriate phenol. All of these compounds are readily and reversibly bxidized to the quinoid structures by oxidation using any convenient oxidant I5 such as hydrogen peroxide.
Conditions that result from vascular hyperpermeability include atherosclerosis and diseases related to atherosclerosis, including heart attack, stroke, and peripheral vascular disease. _ w Compounds of formula I, II or III are especially well suited for treating and preventing atherosclerosis.
By the terms "preventing" and "treating" applicant does not intend that the disease or condition must be completely abolished, only that there is some amelioration, i.e. that its normal course be substantially diminished, so that an improvement over the expected symptomology is clinically observable.
In another aspect, the present invention relates to a method for predicting the risk of a human patient to diseases, such as atherosclerosis, that result from endothelial hyperpermeability. The method comprises identifying a patient having elevated NADPH oxidase activity. Elevated NADPH
oxidase activity is defined for the purpose of the present invention as more than 10% above the range found in paired controls. Such identification is S preferably done by measuring the NADPH oxidase activity in white blood cells (polymorphonuclear leukocytes) of the patient. Polymorphonuclear leukocyte (PMN) NADPH oxidase activity may be measured using flow cytometry with 2,7-dichlorofluorescein diacetate as the indicator.
After identifying such a patient, administration of an NADPH oxidase inhibitor, such as apocynin,. can be recommended for preventing or treating atherosclerosis and its~related diseases.
In each aspect of the invention, administering an NADPH oxidase inhibitor is intended to encompass the administration of compounds which are themselves NADPH oxidase inhibitors, as well as compounds that are metabolic precursors thereto (i.e., prodrugs).
The operative feature is the inhibition of NADPH
oxidase as a result of the administration of the compound in question.
Definitions The following terms have the indicated meaning throughout:
"Alkyl" is intended to include linear, branched or cyclic hydrocarbon structures and combinations thereof. "Lower alkyl" means alkyl groups of from 1 to 8 carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, s-and t-butyl, pentyl, hexyl, octyl, cyclopropylethyl, bornyl and the like. Preferred alkyl groups are those of CZO or below.
"Cycloalkyl" is a subset of alkyl and includes cyclic hydrocarbon groups of from 3 to 8 carbon atoms. Examples of lower cycloalkyl groups include c-propyl, c-butyl, c-pentyl, norbornyl and the like.
"Heterocycloalkyl" means a cycloalkyl where one to two of the methylene (CHz) groups is replaced by a heteroatom-such as ), NR (wherein R is H or alkyl), S
or the like. Examples of heterocycloalkyl include tetrahydrofuranyl, piperidine, dioxanyl and the like.
"Alkenyl" includes CZ_e unsaturated hydrocarbons of a linear, branched or cyclic (CS_6) configuration and combinations thereof. Examples of alkenyl groups include vinyl, allyl, isopropenyl, pentenyl, hexenyl, c-hexenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl and the like.
"Alkynyl" includes Cz_8 hydrocarbons of a linear or branched configuration and combinations thereof containing at least one carbon-carbon triple bond.
Examples of alkynyl groups include ethyne, propyne, butyne, pentyne, 3-methyl-1-butyne, 3,3-dimethyl-1-butyne and the like.
"Aryl" and "heteroaryl" include a 5- or 6-membered aromatic or heteroaromatic ring containing 0-3 heteroatoms selected from O, N and S; a bicyclic 'r 9- or 10-membered aromatic or heteroaromatic ring system containing 0-3 heteroatoms selected from O, N
and S; or a tricyclic 13- or 14-membered aromatic or heteroaromatic ring system containing 0-3 heteroatoms . WO 97/19679 PCT/US96/19053 selected from 0, N and S; each of which rings is optionally substituted with 1-3 lower alkyl, substituted alkyl, substituted alkynyl, =O, -NO2, halogen, hydroxy, alkoxy, -OCH(COOH)2, cyano, -NR4R' (wherein R' is independently H, lower alkyl or cycloalky, and -R°R4 may be fused to form a cyclic ring with N), acylamino, phenyl, benzyl, phenoxy, benzyloxy, heteroaryl or heteroaryloxy; each of said phenyl, benzyl, phenoxy, benzyloxy, heteroaryl and heteroaryloxy is optionally substituted with 1-3 substituents selected from lower alkyl, alkenyl, alkynyl, halogen, hydroxy, alkoxy, cyano, phenyl, benzyl, benzyloxy, caboxamido, heteroaryl, heteroaryloxy, -NOz and --NR4R4. The aromatic 6- to 14-membered carbocyclic rings include, e.g., benzene, naphthalene, indane, tetralin and fluorene, and the 5- to 10-membered aromatic heterocyclic rings include, e.g., imidazole, pyridine, indole, thiophene, benzopyranone, thiazole, furan, benzimidazole, quinoline, isoquinoline, quinoxaline, pyrimidine, pyrazine, tetrazole and pyrazole.
"Alkoxy" refers to groups of from 1 to 8 carbon atoms of straight, branched or cyclic configuration and combinations thereof. Examples include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy and the like.
"Acylamino" refers to groups of from 1 to 8 carbon atoms of a straight, branched or cyclic configuration and combinations thereof. Examples include acetylamino, butylamino, cyclohexylamino and the like.
"Halogen" includes F, C1, Br and I.
"Arylalkyl" refers to an alkyl residue attached to an aryl ring. Examples include, e.g., benzyl, phenethyl and the like.
"Heteroarylalkyl" refers to an alkyl residue attached to a heteroaryl ring. Examples include, e.g., pyridinylmethyl, pyrimidinylethyl and the like.
"Substituted" alkyl, cycloalkyl, heterocycloalkyl, alkenyl or alkynyl refers to alkyl, cycloalkyl, heterocycloalkyl, alkenyl or alkynyl wherein up to three H atoms on each C atom therein are replaced with halogen, hydroxy, loweralkoxy,' carboxy, caboalkoxy, carboxamido, cyano, carbonyl, -NOz, NRSRS (wherein RS is H, alkyl or arylalkyl) , alkylthio, sulfoxide, sulfone, acylamino, amidino, phenyl, benzyl, heteroaryl, phenoxy, benzyloxy, heteroaryloxy and substituted phenyl, benzyl, heteroaryl, phenoxy, benzyloxy or heteroaryloxy.
Brief Descrit~tion of the Drawings These and other objects, features and advantages .
of the invention will be evident from the following detailed description when read in conjunction with the accompanying drawings in which:
Figure 1 is a graph of optical density from fluorescence spectroscopy, measured as "ILIGV", per cell for four test groups of endothelial cells, showing the effect of apocynin on high-LDL induction of endothelial cell peroxide production;
Figure 2 is a graph of fluorescence per 105 cells for four test groups of endothelial cells, showing the effect of apocynin on high-LDL induction of endothelial cell endocytosis;
Figure 3 is a graph of optical density from fluorescence spectroscopy, measured as "ILIGV", per cell for four test groups of endothelial cells, showing the effect of apocynin on arachidonic acid induction of endothelial cell peroxide production;
Figure 4 is a printed reproduction of a photomicrograph of a section of abdominal aorta from a rabbit fed a high cholesterol diet;
Figure 5 is a printed reproduction of a photomicrograph of a section of abdominal aorta from a rabbit fed a high cholesterol diet and also given apocynin according to the invention;
Figure 6 is a bar graph showing the percent increase in H202 production (i.e. elevation of oxidase activity) for each of 22 patients with atherosclerosis compared to a paired control;
Figure 7 is a printed reproduction of a Western-blot of the cytosolic and membrane fractions from control endothelial cells, PMA-exposed endothelial cells and PMA-exposed endothelial cells treated with 100 ~.g/ml apocynin showing the absence of p47 ~phoX~ in the membrane fraction; and Figure 8 is a graph showing OZ- generation by whole cell endothelial cell sonicate in response to arachidonic acid, in the presence and absence of apocynin and purified apocynin dimer.
Detailed Description of the Invention The present invention provides a method for preventing and treating atherosclerosis and diseases related thereto, conditions associated with increased endothelial permeability. According to the invention, the administration of an NADPH oxidase inhibitor, such as apocynin, inhibits NADPH oxidase activation in endothelial cells. The activation of NADPH oxidase is the major cellular source of the oxidative-burst (an intensified generation of reactive oxygen species), which is associated with serum LDL levels that are known to be atherogen~ic.
The oxidative burst modulates heightened endocytosis and endothelial hyperpermeability.
The present invention additionally provides a diagnostic method for predicting the risk of atherosclerosis-related diseases by measuring NADPH
oxidase activity. Individuals with a clinically documented history of atherosclerotic-related diseases, or strong family history thereof, have higher NADPH oxidase activity than people without any medical or family history of the diseases.
A preferred NADPH oxidase inhibitor according to a method of the present invention is apocynin.
Apocynin is an orthomethoxy-substituted catechol that acts to block NADPH oxidase complex assembly by inhibiting the translocation of the p47~phoX~ cytosolic oxidase subunit to the membrane fraction. Studies 'r were performed in which EC were exposed to 10 nM PMA
in the presence and absence of 100 ug/ml apocynin for -15 minutes. Subsequently, EC cytosolic and membrane fractions were isolated. Western-blot analysis of the fractions was performed using the monoclonal antibody against p47~p,,ox] . Figure 7 reveals the absence of the cytosolic subunit p47~phox~ in the membrane fraction of EC treated with apocynin.
While a preferred NADPH oxidase inhibitor in the present invention is apocynin, the method of the invention is not limited to apocynin, and a variety of other chemicals known to inhibit NADPH oxidase in endothelial cells may be used, as will be obvious to those skilled in the art. In the case of apocynin, the intact molecule (the ortho-methoxy phenol.) appears to be effective as an inhibitor, and in~' addition, a dimer arising from metabolic oxidation is also highly effective and indeed may be the active species. Thus, compounds having an electron distribution similar to that in the dimer are effective inhibitors of NADPH oxidase and are contemplated within the invention. Examples of other types of NADPH oxidase inhibitors that may be useful include, but are not limited to, isoprenylation inhibitors such as lovastatin and compactin (see U.S.
patent 5,224,916), benzofuranyl- and benzothenylthio-alkane carboxylates (see EP application 551,662), and cytochrome bsse fragments and their analogs (see PCT
application WO 91/17763).
While it is believed that many of the known NADPH oxidase inhibitors act by interfering with the assembly of the active complex, the term NADPH
oxidase inhibitor, as used herein, is not intended to be restricted as to mechanism. Any substance that inhibits the NADPH oxidase-catalyzed generation of reactive oxygen species is encompassed by the term "NADPH oxidase inhibitor". The claimed method for treating atherosclerosis by NADPH oxidase inhibitors can be distinguished from the known methods for S
treating atherosclerosis (although the mechanism was previously unknown) employing compounds that happen also to be NADPH inhibitors. The claimed method can employ doses of known inhibitors (e. g. lovastatin) that would be therapeutically ineffective to reduce LDL-cholesterol, i.e. that produce a less than 100 lowering of serum LDL-cholesterol.
Alternatively, the claimed method employs inhibitors that are targeted to the NADPH oxidase complex in that they have a lower ICso vs human~NADPH
oxidase than vs human HMG-CaA reductase. For the purpose of the present invention, the ICSO is defined, according to standard practice, as the concentration of inhibitor required to inhibit the enzyme in question by 50%. The ICSO vs human NADPH oxidase is measured as described in US patent 5,244,916 column 11-12; the ICso vs human HMG-CoA reductase is measured as described by Edwards et al. [J. Lipid Res. 20, 40-46 (1979)]. A brief description of the HMG-CoA
reductase measurement is as follows:
A fragment of human liver is homogenized at 4° C
in 25 mL of buffer A (0.1 M sucrose, 0.05 M KC1, 0.04 M potassium phosphate and 0.03 M potassium EDTA; pH
7.2) and the microsomes are prepared as described by Edwards and Gould [J. Biol. Chem. 247, 1520-1524 (1972)]. The microsomes are resuspended in buffer A
to a concentration of approximately 82 mg protein/mL, solid DTT is added to a final concentration of l0 mM
and the microsomes are homogenized. Three mL
aliquots of the microsome suspension are frozen in glass tubes at a rate of 6-8° C per min as described by Heller and Gould [Biochem. Biophys. Res. Comm. 50, 859-865 (1973)], and stored at -20° C far up to two months.
For optimal solubilization of the reductase, the frozen microsomes are allowed to thaw at room temperature before addition of an equal volume of 50%
glycerol in buffer B (buffer A plus 10 mM DTT) preheated to 37° C. The suspension is rehomogenized and then incubated at 37° C for 60 minutes. The suspension-is diluted threefold with buffer B
preheated to 37° C to a final glycerol concentration of 8.3%, rehomogenized and centrifuged at 100,000 g for 60 minutes at 25° C-. The supernatant, containing solubilized HMG-CoA reductase, is removed and used immediately.
The activity of the solubilized HMG-CoA
reductase is determined at 37° C in a total volume of 0.5 mL using a spectrophotometer. The cell path length is 1.0 cm. The rate of oxidation of NADPH is initially determined in the absence of HMG-CoA and this blank value, if any, is subtracted from the rate obtained with both substrates.
Maximum activity is obtained by assaying the enzyme in buffer C (0.2 M KC1, 0.16 M potassium phosphate, 0.004 MEDTA, and 0.01 MDTT, pH 6.8) together with 0.2 mM NADPH and 0.1 mM RS-HMG-CoA.
One unit of enzyme activity is defined as the amount required to oxidize 2 nmol NADPH per minute. Hence, one unit is equivalent to the synthesis of 1 nmol mevalonate per minute.
Inhibition is measured in buffer C. The results are expressed as the 50% inhibitory concentration (ICSo) for the test substance. Six to ten test substance concentrations, separated by approximately 1/2 log, are tested in duplicate. The test substances are dissolved in buffer C for addition to the incubations. The ICSa is calculated by linear interpolation.
A class of inhibitors that inhibits NADPH
oxidase but does not block isoprenylation can be distinguished by the fact that they effect .
statistically equivalent inhibition of human NADPH
oxidase in the presence and absence of mevalonate (see US patent 5;244,916, column 14, line 60 to column 15, line 30).
In Vitro Apocynin Experiments Experiments were performed in vitro using a high LDL endothelial cell tissue culture system.
Endothelial cells were isolated from human umbilical -.' cord veins and placed in experimental wells to which LDL media were added. The tissue culture components and chemicals are commercially available and were obtained from Sigma, Worthington, and Gibco. LDL was isolated from human blood plasma. Apocynin is available from Carl Roth GmbH (Germany).
Studies were conducted using apocynin to block NADPH oxidase activation and thereby prevent _ heightened endocytosis. Apocynin interferes with the assembly of a functional NADPH oxidase enzyme ;
complex. For apocynin studies, EC were incubated with 240 mg/dL LDL cholesterol in the presence and absence of 100 ~.g/mL apocynin. As shown in figures 1 and 2, apocynin effectively inhibits (1) the induction of HzOz production and (2) endocytosis alterations associated with high concentrations of LDL.
As mentioned above, arachidonic acid activates EC NADPH oxidase directly, by inducing EC Hz02 generation; exposure to arachidonic acid promotes heightened EC endocytosis.
l0 Further support that the arachidonic .
acid-induced oxidative burst results from NADPH
oxidase activation is provided from the results of the following test in which apocynin was used to block NADPH oxidase activation. EC were incubated with 10 ~M arachidonic acid in the presence and absence of 100 ~.g/mL apocynin. Figure 3 shows that apocynin markedly reduces arachidonic acid-induced EC
H202 generation.
It has been demonstrated that there is a lag time of approximately two minutes before apocynin acts to inhibit NADPH oxidase activity. This delay results from the time required for apocynin to be metabolized to an active product in a chemical reaction involving ROS and peroxidase. Following this delay in effect, cellular ROS production is nearly completely inhibited.
The active metabolite of apocynin has been identified as a dimer possessing a quinone-like structure which arises from metabolic oxidation.
Studies were performed to examine ROS generation by whole cell EC sonicate, in response to arachidonic acid, in the presence and absence of the purified apocynin dimer. As seen in Figure 8, there was no ;
lag time for the nearly complete inhibition of ROS
generation in the presence of the purified apocynin dimer.
DIMERIZATION OF APOCYNIN
~~ H i w_ H
H O_[H3 ti ~ 0 H f_H~
H H i i ~. n ~ i i :i ~H <~ ~ ~ -_ sH~.. P=1'.:~;'ir_Id5= ~ ~.~~r H
r ~JCH_, Synthesis and Isolation of Apocvnin Dimer I. Synthesis A 0.02 mg/ml aqueous solution of apocynin is prepared by dissolving 10 mg apocynin volumetrically in 500 mL distilled H20. The final molarity of the solution is 1.2 x 10-4 M. A 3% H2O2 (m/m) solution is ~-prepared by diluting 1 mL of 30% H202 (m/m, 9.8 M) to 10 mL volumetrically with distilled HZO. The final molarity of the solution is 0.98 M. A 0.1 mg/mL
solution of horseradish peroxidase (HRP) is prepared by dissolving 5 mg of solid HRP in 50 mL distilled HZO
volumetrically.
100 mL of 0.02 mg/mL apocynin solution is combined with 100 uL (delivered via micropipette) of 0.1 mg/mL HRP solution in a clean, dried 250 mL
erlenmeyer flask. A magnetic stir bar is added and the solution is stirred gently. The reaction is initiated by the addition of 24 ~.L (delivered via micropipette) of the 3% Hz02 solution. After 10 seconds, the reaction mixture is quenched by the --addition of 1.5 mL of 0.1 M NaZS203. The solution is then allowed to stir vigorously for 2 minutes, at the end of which the pH of the solution is reduced to 3 to 4 by the addition of 5 drops 3 M HZS04 The quenched reaction mixture is then divided into two 50 mL portions. Each portion is extracted twice with diethyl ether (2 x 15 mL) and the ether layers are combined. The combined ether extracts are dried for .l0 minutes over a minimal amount of anhydrous MgS09, and then gravity filtered. The, ether is removed by rotary evaporation, and the resulting product, primarily a mixture of apocynin and apocynin dimer, is dissolved in CDC13 for analysis by 1H-NMR
Spectroscopy.
II. Isolation After analysis by 1H-NMR, CDC13 is removed by rotary evaporation, and the crude product mixture is dissolved in a minimal volume of HPLC Grade methanol (<1 mL). If suspended particles exist, a nylon membrane syringe filter is used to filter the solution prior to injection onto the HPLC column. To isolate the dimer, reverse phase (C18) HPLC equipped with a W detector is employed in a preparatory manner. The mobile phase is 50:50 methanol: acetate buffer (pH=4) and a 260 nm wavelength is used for detection.
Methanol is removed from the collected preparatory solution containing the dimer (10 to 20 mL) by rotary evaporation (approximately 1 hour).
WO 97/19677 PC'T/US95/15587 A solid phase extraction filter cartridge (Alltech C18 500 mg - 3 mL) is then prepared by pulling 10 mL HPLC Grade methanol, followed by 10 mL
distilled H20 through the filter. The stripped preparatory solution is passed through the filter, followed by a 4 mL distilled Hz0 rinse. The filter is allowed to dry for approximately 10 minutes, then HPLC Grade methanol aliquots are pushed through the column and collected (5 x 5 mL). The methanol is removed by rotary evaporation, and the isolated dimer , is dissolved in 3 mL CDC13. The dimer is then analyzed by 1H-NMR spectroscopy. ~ .
REDOX REACTION FOR APOCYNIN DIMER
H U H CH3 H \ U H CH3 CH3 ~ p ~,~,~ i dat i on] CH3 ~ ~ ( 0 0 H 0 H \
OH~H ( r'aduct i on] ~ O~H
While applicant does not wish to be limited by the hypothesis, it appears that apocynin may be a metabolic precursor of the species that actively inhibits NADPH oxidase.
Additional studies were conducted to provide further insight into the mechanism of NADPH oxidase activation. The cellular enzyme, phospholipase AZ
(PLAZ) hydrolyses membrane phospholipids releasing arachidonic acid intracellularly. PLA2 inhibition by its antagonist, p-bromophenacyl bromide (BPB).
suppresses the rise in cytosolic free arachidonic acid and limits this secondary messenger for NADPH
oxidase activation. Thus, PLAZ inhibition blocks LDL-EC NADPH oxidase activation. In these studies, VlfO 97/19679 PCT/US96/19053 EC were exposed to 240 mg/dL LDL-cholesterol with and without IO ~.M BPB. BPB markedly diminished LDL-EC
reactive oxygen species production.
PLAz is a Caz'-dependent enzyme . Likewise, Ca2' is required for NADPH oxidase activation in intact cells. PLAZ-mediated arachidonic acid release parallels extracellular Caz' concentration. Studies were conducted to determine whethcer LDL-EC have increased cellular Cap' influx. In these studies, EC
were incubated with increasing LDL levels (30 to 240 mg/dL cholesterol), and cellular Caz' influx was measured employing a "SCaz' uptake assay as described by Lewis et al. [J. C1'in. Invest., 82, 2045-2055 (1988)]. It was found that LDL-EC promote a dose-dependent rise in cellular Ca2' influx. LDL may induce Ca2' influx by EC exposure to H20z, causing cellular permeabilization to Cap' and resulting in an intracellular calcium elevation.
The above studies in vitro demonstrated that atherogenic LDL levels induce heightened EC
endocytosis and that reactive oxygen species, produced predominantly by NADPH oxidase, modulate heightened EC endocytosis. To restate, while not intending to be held to any particular theory, one may hypothesize, based on the above studies .in vitro, that reactive oxygen species, generated by activated EC NADPH oxidase, modulate hypercholesterolemia-induced vascular hyperpermeability via heightened EC
endocytosis.
High LDL exposure initially activates phospholipase AZ activity releasing arachidonic acid from phospholipids. Cytoplasmic free arachidonic acid, at a threshold level, converts an inactive genetic variant of NADPH oxidase to its active form.
This genetic NADPH oxidase variant generates increased amounts of reactive oxygen species which _ perturb the cell membrane and enhance PLAZ activation.
PLAZ activation is further enhanced by reactive oxygen species-mediated cellular Caz' influx. Arachidonic acid released from membrane phospholipids markedly escalates NADPH oxidase enzyme complex recruitment and assembly. The multiple, membrane-bound, assembled-enzyme complexes. generate excessive quantities of reactive oxygen species, Oz- and HzOz.
These reactive oxygen species increase membrane' fluidity and decrease the energy of activation for endocytosis. The combination of these LDL-induced cellular events result in heightened EC endocytosis, vascular hyperpermeability, and~increased transcellular transport via transcytosis.
Thus, inhibition of NADPH oxidase activation with apocynin, for example, prevents heightened EC
endocytosis and reduces vascular hyperpermeability.
While not wishing to be restricted to a particular theory, it is possible that the inhibition of NADPH oxidase by the apocynin dimer may involve the disruption of the electron transport chain in the NADPH oxidase activation process. NADPH Oxidase activation requires the coupling of electron transport function between ubiquinone (co-enzyme Q) and cytochrome b. An oxidized dimer having a lower reduction potential than ubiquinone would then block the electron transport chain. ':
In Vivo Apocynin Experiments To test the foregoing hypothesis, studies were conducted in vivo, which focused on the effect of NADPH oxidase inhibition on vascular hyperpermeability using a hypercholesterolemic rabbit model. New Zealand white male rabbits were placed on a is cholesterol diet with (n=5) and without (n=5) 200 ~cg/mL apocynin added to their drinking water.
After one month from commencement of feed, animals were infused with horseradish peroxidase (HRP) as a permeability tracer one minute prior to sacrifice.
The aortas were excised, opened, and pinned to~a dissecting tray. Gross visual inspection revealed that aortas of 1% cholesterol-fed rabbits without apocynin treatment had typical, diffuse early.
atherosclerotic lesions. In contrast, an absence of lesions was noted in the aortas of hypercholesterolemic rabbits treated with apocynin.
Subsequently, aortas were exposed to diaminobenzidine and H20a, and a brown reaction precipitate developed at sites of high HRP concentrations. Aortas of hypercholesterolemic rabbits without apocynin treatment had marked, diffuse areas of high HRP
concentrations. However, aortas of hypercholesterolemic animals treated with apocynin consistently showed few HRP-positive areas, a pattern similar to that seen in rabbits fed standard rabbit chow. The total serum cholesterol levels of hypercholesterolemic rabbits with and without = 30 apocynin treatment were comparable.
A three month study was also carried out using ten New Zealand white male rabbits fed a 1%
cholesterol diet with 30 ~,g/mL (n=2), 200 ~.g/mL
(n=2), 400 ~g/mL (n=2), 800 ug/mL (n=2), and without (n=2) apocynin added to their drinking water. After three months, the animals were sacrificed, and their aortas were examined as before. Visual inspection revealed that aortas of 1% cholesterol-fed rabbits without apocynin treatment had in the range of 60% of aortic surface area covered with atherosclerotic plaque. In contrast, a dose-dependent diminution of lesions was noted in the aortas of hypercholesterolemic rabbits treated with apocynin.
In animals treated with greater than 200 ~,g/mL of apocynin, aortic surface covered with plaque. was reduced to less than 8%. The total serum cholesterol levels of hypercholesterolemic rabbits with and without apocynin treatment were comparable at about 1000 mg/dL.
Morphologic examination of aortic endothelium from the one and three-month rabbits was performed.
Random tissue samples were taken from the thoracic and abdominal aortas of hypercholesterolemic rabbits and hypercholesterolemic rabbits treated with apocynin. Tissue samples were thin sectioned and processed for microscopy. Examination of electron and light micrographs from hypercholesterolemic rabbits without apocynin treatment revealed frequent and diffuse vascular changes characteristic of atherosclerotic disease. Figure 4 is a representative light micrograph. In contrast, examination of multiple tissue samples from hypercholesterolemic rabbits with apocynin treatment '-revealed little evidence for vascular changes.
Figure 5 is a representative light micrograph. The effect of NADPH oxidase inhibition on coronary artery endothelium was similarly examined. Like the abdominal aorta, the coronary artery was found to exhibit vascular changes characteristic of atherosclerotic disease, and these changes were attenuated by treatment with apocynin.
To provide experimental evidence that apocynin reduces vascular hyperpermeability by preventing heightened EC endocytosis from occurring, the number of endocytotic vesicles on EC luminal and abluminal sides from electron micrographs were counted as an approximate measure of endocytotic activity.
Electron micrographs of 50 randomly selected~cells from aortas of hypercholesterolemic rabbits treated with and without apocyriin were taken at 35,OOOX
magnification. Endocytotic vesicles were counted on luminal and abluminal cell sides. Vesicles counted included those that were forming in the plasma membrane or clearly attached to the membrane. A
significant decrease in the number of endocytotic vesicles in apocynin treated animals was observed, suggesting that apocynin acts by averting endocytosis increases.
Side Effects Rabbits treated with apocynin for a three month period demonstrated no overt signs of ill health.
Weight gain, over the three month period, for apocynin-treated rabbits was comparable to those animals without apocynin treatment.
One might have expected that apocynin might increase susceptibility to infections, since white blood cells use NADPH oxidase to generate ROS to kill bacteria. However, no increased incidence of WO 97!19679 PC'T/US96/19053 infections in the New Zealand White male rabbits was seen.
Another theoretical side effect of apocynin .
might have been thought to result from inhibition of cell 'proliferation. Certain tissues of the body, including bone marrow and gastrointestinal cells, have higher cell proliferation rates. Cell growth studies showed the dose-dependent effect of apocynin on endothelial and smooth muscle cell proliferation.
At 100 ~Cg/mL apocynin, the cell proliferation rates were minimal, however, visual inspection of the cells revealed no evidence of cell injury or death at'the apocynin concentrations-tested. Thus, at concentrations that inhibit ROS generation, apocynin is highly effective at suppressing cell proliferation.
Conclusion The above studies in vitro and in vivo indicate that the administration of NADPH oxidase inhibitors, such as apocynin, can prevent and treat diseases associated with hyperpermeability of endothelial cells, including atherosclerosis and its related diseases. In addition to the prevention of atherosclerosis, NADPH oxidase inhibitors, such as apocynin, may be useful for the prevention and treatment of the following conditions by decreasing membrane permeability and cell proliferation associated therewith: arthritis, cancer, sepsis; ..
post-stroke and post-MI tissue swelling and reperfusion injury; adult respiratory distress syndrome CARDS); growth malignancies; post-transplant vascular changes; vasculitides; asthma and diabetes mellitus.
The optimal dose of the NADPH oxidase inhibitor, such as apocynin, to be used in humans will vary depending upon the severity and nature of the condition to be treated, the route of administration, the age, weight, and sex of the patient, as well as on any other medications being taken by the particular patient or the existence of any complicating significant medical conditions of the patient being treated. The dose and perhaps.the dose frequency will also vary according to the response of the individual patient.' In general, the total daily dose range for apocynin for the conditions described herein is from about 10 mg/kg/day to about 45 mg/kg/day; for the average human, the total dose is about 500 mg to about 3000 mg daily, preferably in divided doses. In managing the patient, the therapy should be initiated at a lower dose, perhaps at about 200 mg to about 500 mg, and increased up to about 1000 mg depending on the patient's global response.
It is further recommended that patients over 65 years and those with impaired renal or hepatic function initially receive low doses and that they be titrated based on individual responses) and blood level(s).
It may be necessary to use dosages outside these ranges in some cases, as will be apparent to those skilled in the art. Further, it is noted that the clinician or treating physician will know how and when to interrupt, adjust, or terminate therapy in conjunction with individual patient response. The terms "a therapeutically effective amount" and "an amount sufficient to prevent" a condition are encompassed by the above-described dosage amounts and dose frequency schedule.
z Any suitable route of administration may be employed for providing the patient with an effective dosage of apocynin. For example, oral, rectal, parenteral (subcutaneous, intramuscular, intravenous), transdermal, aerosol and like forms of administration may be employed. Oral dosage is preferred.
Studies on Prediction of Risk of Atherosclerosis If a heightened endocytosis mechanism predominantly involves an endothelial cell defect rather than an atherogenic LDL type, one could explain why certain people with plasma LDL levels commonly associated with atherosclerosis do not develop atherosclerotic-related diseases. The EC
defect hypothesis would also suggest that atherosclerotic patients should exhibit in common some elevation in NADPH oxidase activity.
To test the hypothesis, 92 high LDL-EC
endocytosis experiments with cell isolates from 92 separate human umbilical cords were conducted in vitro. In addition, LDL preparations, isolated weekly from different human sources, were generally used on EC isolates derived from two or more human sources, thus allowing for analysis of LDL's effect.
Endothelial cells from the same cord all had similar ',-endocytotic activity with exposure to high LDL
levels. In contrast, EC from different cord sources .
responded differently, ranging from no endocytosis change to 200-300% increases in endocytotic activity over control cells.
In 52% of EC isolates tested, high LDL exposure induced a wide variation in degree of response ranging from 5 to 300% endocytosis increases. This observation in vitro correlates with epidemiologic studies that indicate that mortality from atherosclerotic-related diseases occurs in approximately 50% of the population.
If, contrary to the EC hypothesis, an -atherogenic LDL type exists, one would expect that EC
isolates from multiple human sources would all have similar responses when exposed to the same LDL
preparation. EC isolates tested were classified as no response (0 to 5% endocytosis increase) or response (5 to 300% endocytosis increase) and analyzed. Results showed that in only 53% of experiments did all EC isolates, exposed to the same LDL preparation, either respond or have no response.
The importance of this finding is that it suggests the likelihood that the heightened endocytosis mechanism predominantly involves an EC defect rather than an atherogenic LDL type. Thus, high levels of LDL's appear to activate the heightened endocytosis mechanism.
This finding explains why certain people with plasma LDL levels commonly associated with atherosclerosis do not develop atherosclerotic-related diseases and leads to the inventive method for predicting an individual's risk of atherosclerosis. By identifying a patient having elevated NADPH oxidase activity' one can predict an increased risk of atherosclerosis. Administration of apocynin or other NADPH oxidase inhibitor can then be recommended for preventing atherosclerosis and its related diseases to those identified patients.
If genetic variants of NADPH oxidase or enzymes involved in its activation exist in the human population, and some of these variants generate excessive amounts of reactive oxygen species, this should correlate with clinical atherosclerosis.
Human studies were therefore undertaken. In theses studies, the polymorphonuclear leukocyte (PMN) NADPH
oxidase activity in individuals having a history of clinically documented atherosclerosis-related diseases or strong family history thereof was compared with that of individuals having no medical or family history of the diseases. Volunteers provided a medical and family history of atherosclerotic related diseases and a venous blood sample. PMN NADPH oxidase activity was measured by flow cytometry with a fluorescent probe, using 2,7-dichlorofluorescin diacetate as indicator. NADPH
oxidase activity was determined by taking fluorescent measurements from the PMN gated window. For these studies, 22 individuals with either clinically documented medical or family history of atherosclerotic-related diseases (experimental) were compared to 11 individuals (controls) with no clinical evidence of or family history of the diseases.
The results, as illustrated in Figure 6, reveal that the 22 experimental human subjects had significantly increased NADPH oxidase activity over their paired controls (Probability for significance 'vV0 97/19679 PCT/US96/19053 of test: P < 0.07). The findings suggest that genetic variants of NADPH oxidase (or enzymes involved in its activation) exist, and that people with these genetic variants are at higher risk of atherosclerotic-related diseases.
While the invention has been particularly shown and described with reference to preferred embodiments thereof, it will be understood by those skilled in the art that other changes in form and details may be made therein without departing from the spirit and scope of the invention.
Many pharmaceutical agents have been developed to treat or prevent atherosclerosis and its complications by controlling abnormally high blood LDL levels or lowering cholesterol levels. The most widely known of these agents include nicotinic acid, clofibrate; dextrothyroxine sodium, neomycin, beta-sitosterol, probucol, cholestyramine and HMG-CoA
reductase inhibitors, such as lovastatin and simvastatin. However, the usefulness of these agents is limited by the frequent occurrence of acute side effects. Such side effects may include intense cutaneous flush, pruritus, gastrointestinal irritation, hepatotoxicity, cardiac arrhythmias, nausea, weight gain, alopecia, impotence, abdominal pain, diarrhea, eosinophilia, skin rash, musculoskeletal pain, blurred vision, mild anemia, ,_ leukopenia, the enhancement of gallstones, constipation, and impaction. Moreover, there is only a partial correlation between lowering of serum cholesterol and the reduction of atherosclerosis.
Not all patients with atherosclerotic disease have high cholesterol and not all patients with high cholesterol have atherosclerotic disease.
The pathobiology of atherosclerosis indicates a major role for vascular endothelial involvement. ' Perturbation of the endothelium, without overt death and loss of endothelial cells, with resultant change in endothelial permeability to various blood materials is an important feature in the development of atherosclerotic lesions. Materials contained in the blood subsequently pass through this endothelial tissue and accumulate in the intima of the arterial wall. Even a moderate increase in endothelial permeability (hyperpermeability) is accompanied by a significant increase in the incidence of atherosclerotic events.
One mechanism by which vascular hyperpermeability can occur in the presence of an intact endothelium is increased endothelial endocytosis due to perturbation of the endothelium. The endothelium can be perturbed by various conditions, including high levels of low density lipoprotein (LDL) in the bloodstream and shear stress, as occurs in hypertension. Diabetes mellitus and smoking can also give rise to perturbation of the endothelium. I have conducted studies in which human vascular endothelial cells (EC) were exposed to high LDL concentrations (up to 330 mg/dL cholesterol) for prolonged periods. The 2o results, as demonstrated by stability of cell count for instance, indicate that EC death and loss do not occur in humans during the promotion of atherosclerotic plaque formation by LDL.
Initially, endothelial perturbation occurs, resulting in increased endocytosis and LDL
accumulation in the subendothelial space. Thus, exposure to high LDL levels induces heightened EC
endocytosis. Studies indicate that exposure to LDL, in concentration ranges that are considered from epidemiologic studies to be atherogenic (endothelial cells exposed to >140 mg/dL LDL cholesterol, for example), is necessary for exaggerated endocytosis.
Another key finding is that once heightened endocytosis develops, it persists. Such a persistent change in EC functional state is consistent with the endothelial perturbation, or vascular hyperpermeability, concept.
Endocytosis is a fundamental, apparently ubiquitous, cellular event. During endocytosis, a segment of plasma membrane is interiorized to form a vesicle that migrates into the cytoplasm. This vesicle may participate in transcellular transport via transcytosis. The endocytosis regulatory mechanism is not well understood, but my studies demonstrate that reactive oxygen species, such~as HZOZ
and OZ-, modulate heightened EC endocytosis. Cells generate reactive oxygen species (ROS) as byproducts of normal cellular metabolism. Perturbed endothelial cells increase reactive oxygen species production via the activation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase.
NADPH oxidase is an enzyme that has been well characterized in leukocytes, but leukocyte-type NADPH
oxidase has not been previously identified in endothelial cells. I have demonstrated that it occurs in endothelial cells. Activation of NADPH
oxidase results in the transfer of electrons from NADPH to oxygen, resulting in the generation of reactive oxygen species (ROS) such as OZ- and Hz02.
The active form of the oxidase is a complex assembled from membrane-bound proteins that include cytochrome bsse ( Composed of gp91 ~Phox~ and p22 ~phox] ) and cytosolic components, of which three have been characterized, P4~ (phoxl ~ P67 [phox] and a low molecular weight GTP-binding protein. Cytochrome b55a consists of a 22 kD
polypeptide which tightly binds to a glycosylated 91 _5_ kD polypeptide. The glycosylated 91 kD polypeptide is an integral membrane protein that serves to anchor the 22 kD polypeptide.
It is known that inheritable abnormalities of the NADPH oxidase enzyme complex result in Chronic Granulomatous Disease (CGD), a congenital disorder in which leukocytes are unable to generate reactive oxygen species in response to microorganisms.
Studies on CGD, in which NADPH oxidase activity is insufficient or absent, have shown that genetic variants of NADPH oxidase exist. There have been no studies, though, to identify NADPH oxidase genetic variants that produce excessive amounts of reactive oxygen species. If such variants exist and are common in our population, then people inheriting these genetic variants may be at higher risk of heart attack, stroke, and peripheral vascular disease.
The membrane-bound enzyme, NADPH oxidase, exists in an inactive form in quiescent cells. Upon cell perturbation, the enzyme complex assembles and is converted into an active state causing intensified reactive oxygen species generation (oxidative burst).
Studies attempting to delineate the NADPH oxidase activation mechanism indicate that unsaturated fatty acids, most potently arachidonic acid, directly activate NADPH oxidase. To ascertain if arachidonic acid activates the NADPH oxidase found in endothelial cells, studies were carried out in which cells were directly exposed to increasing arachidonic acid concentrations and reactive oxygen species production was measured. For these studies, EC were incubated with 1 to 25 ~cM arachidonic acid and H20z production measured. It was shown that arachidonic acid both induces EC HZOZ generation and promotes heightened EC
endocytosis.
One explanation for the correlation between high LDL and atherosclerosis based on the above S information is that exposure to high levels of LDL~s promote phospholipase AZ activation. At an intracellular threshold level, cytosolic free arachidonic acid converts NADPH oxidase from a dormant to an active state.
Evidence from my experiments indicates that reactive oxygen species modulate heightened '' endocytosis, a characteristic of atherosclerosis, and that NADPH oxidase is the major cellular source.
Although NADPH oxidase inhibitors are claimed to be effective in treating inflammatory conditions, they have not been heretofore suggested to treat diseases such as atherosclerosis, whose initial phase is characterized by increased endocytosis and vascular hyperpermeability. For example, European patent application 551662 discloses the use of NADPH oxidase inhibitors to control acute and chronic inflammations of the airways, joints, and blood vessels. Such inflammations of the vessels include those arterioscleroses that are of inflammatory origin, but the EP application does not envision atherosclerosis, because atherosclerosis is initiated by a metabolic condition, not by inflammation.
The use of 4-hydroxy-3-methoxyacetophenone v (trivial name, apocynin) as an NADPH oxidase inhibitor is known, and it has been suggested to be ', of utility in treating inflammatory diseases.
Apocynin is a natural phenol isolated from the root of the plant Picrorhiza kurroa, which grows in the Himalaya mountains. Extracts of Picrorhiza kurroa have been used in traditional medicine in Southeast Asia for the treatment of diseases connected with inflammation and for the treatment of a variety of conditions including liver and lung diseases, fever, skin lesions, worm infections, rheumatic disease, urinary disorders, heart failure, and snake and scorpion bites. A more recent reference [Engels et al. FEBS Lett., 305, 254-56 (1992)] suggests that apocynin_may also be useful in preventing thrombosis.
However, neither apocynin nor any other NADPH oxidase inhibitor has been shown to prevent atherosclerosis or vascular hyperpermeability attributable to heightened EC endocytosis and high LDL
concentrations.
A method that prevents and treats atherosclerosis and its associated diseases, that is effective in most patients, and that avoids patient-deterring side effects would represent a substantial advance toward eliminating a major cause of death in this country. A method employing a readily available medicament that has already been used in humans would present additional significant advantages in the prevention and treatment of atherosclerosis and related diseases. In addition, a diagnostic method for predicting an individual's potential risk of developing atherosclerosis is highly desirable.
Summarv of the Invention The present invention relates to the surprising discovery of an effective method and composition for treating and preventing atherosclerosis in mammals.
The present invention provides a method for the therapeutic use of an NADPH oxidase inhibitor, preferably apocynin, for the treatment and prevention of conditions resulting from endothelial hyperpermeability, such as atherosclerosis.
Inhibition of NADPH oxidase activation in endothelial cells diminishes vascular hyperpermeability. Other conditions associated with vascular hyperpermeability can also be treated or prevented by administering an NADPH oxidase inhibitor such as apocynin.
In one aspect, the present invention relates to methods for preventing or treating a condition ' resulting from endothelial hyperpermeability. The method comprises administering to a mammal suffering from a condition resulting from endothelial hyperpermeability a therapeutically effective amount of an NADPH oxidase inhibitor or a metabolic precursor to an NADPH oxidase inhibitor. The NADPH
oxidase inhibition that results from the method of the invention may be distinguished by several overla in but distinct, features: (1) the dose of PP g, NADPH oxidase inhibitor or precursor may be insufficient to lower serum LDL by more than 10%; (2) the NADPH oxidase inhibitor or precursor may have a lower ICSQ vs human NADPH oxidase than vs human HMG-CoA reductase; or (3) the NADPH oxidase inhibitor or precursor may effect statistically equivalent inhibition of human NADPH oxidase in the presence and absence of mevalonate.
In another aspect, the invention relates to a method of treating or preventing a condition resulting from endothelial hyper-permeability which comprises administering to a mammal a therapeutically effective amount of a substance which inhibits p47~phax]
translocation to the gp91 ~phoX~ and p22 ~phoX~ membrane bound NADPH oxidase components.
In a preferred aspect of the invention, the NADPH oxidase inhibitor is a compound of the formula:
R
R' _~ hl oR' I
whereu'n R1, R2 and R' are independently chosen from the group consisting of H, alkyl, cycloalkyl, heterocycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl and substituted alkyl, cycloalkyl, heterocycloalkyl, alkenyl and alkynyl.
In another preferred aspect of the invention, the NADPH oxidase inhibitor is of the formula:
R .1 ~ O H
R ~(~)I . ~~ ~~ .<I.0 O
a 0 OH1':Iw'R~ O O~~~.1.'R~
II III
or a tautomer thereof , wherein R1, RZ and R' are independently chosen from the group consisting of H, alkyl, cycloalkyl, heterocycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl and substituted alkyl, cycloalkyl, heterocycloalkyl, alkenyl and alkynyl.
In a more preferred aspect of the invention, the NADPH oxidase inhibitor is of the formula I, II or I I I , wherein R1 and Rz are each methyl and R' is H .
Compounds of the formula I are widely available commercially. Those that are not commercially available can be conveniently prepared by Friedel-Crafts acylation of the appropriate phenol or protected phenol, by aryllithium addition of a protected phenol to the appropriate carboxylic acid or arylcadmium addition to an acid chloride, followed by deprotection, as well as by any of the other well-known methods for forming ketones.
Other-compounds of the genus II may be made in analogous fashion by oxidative dimerization of the appropriate phenol. All of these compounds are readily and reversibly bxidized to the quinoid structures by oxidation using any convenient oxidant I5 such as hydrogen peroxide.
Conditions that result from vascular hyperpermeability include atherosclerosis and diseases related to atherosclerosis, including heart attack, stroke, and peripheral vascular disease. _ w Compounds of formula I, II or III are especially well suited for treating and preventing atherosclerosis.
By the terms "preventing" and "treating" applicant does not intend that the disease or condition must be completely abolished, only that there is some amelioration, i.e. that its normal course be substantially diminished, so that an improvement over the expected symptomology is clinically observable.
In another aspect, the present invention relates to a method for predicting the risk of a human patient to diseases, such as atherosclerosis, that result from endothelial hyperpermeability. The method comprises identifying a patient having elevated NADPH oxidase activity. Elevated NADPH
oxidase activity is defined for the purpose of the present invention as more than 10% above the range found in paired controls. Such identification is S preferably done by measuring the NADPH oxidase activity in white blood cells (polymorphonuclear leukocytes) of the patient. Polymorphonuclear leukocyte (PMN) NADPH oxidase activity may be measured using flow cytometry with 2,7-dichlorofluorescein diacetate as the indicator.
After identifying such a patient, administration of an NADPH oxidase inhibitor, such as apocynin,. can be recommended for preventing or treating atherosclerosis and its~related diseases.
In each aspect of the invention, administering an NADPH oxidase inhibitor is intended to encompass the administration of compounds which are themselves NADPH oxidase inhibitors, as well as compounds that are metabolic precursors thereto (i.e., prodrugs).
The operative feature is the inhibition of NADPH
oxidase as a result of the administration of the compound in question.
Definitions The following terms have the indicated meaning throughout:
"Alkyl" is intended to include linear, branched or cyclic hydrocarbon structures and combinations thereof. "Lower alkyl" means alkyl groups of from 1 to 8 carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, s-and t-butyl, pentyl, hexyl, octyl, cyclopropylethyl, bornyl and the like. Preferred alkyl groups are those of CZO or below.
"Cycloalkyl" is a subset of alkyl and includes cyclic hydrocarbon groups of from 3 to 8 carbon atoms. Examples of lower cycloalkyl groups include c-propyl, c-butyl, c-pentyl, norbornyl and the like.
"Heterocycloalkyl" means a cycloalkyl where one to two of the methylene (CHz) groups is replaced by a heteroatom-such as ), NR (wherein R is H or alkyl), S
or the like. Examples of heterocycloalkyl include tetrahydrofuranyl, piperidine, dioxanyl and the like.
"Alkenyl" includes CZ_e unsaturated hydrocarbons of a linear, branched or cyclic (CS_6) configuration and combinations thereof. Examples of alkenyl groups include vinyl, allyl, isopropenyl, pentenyl, hexenyl, c-hexenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl and the like.
"Alkynyl" includes Cz_8 hydrocarbons of a linear or branched configuration and combinations thereof containing at least one carbon-carbon triple bond.
Examples of alkynyl groups include ethyne, propyne, butyne, pentyne, 3-methyl-1-butyne, 3,3-dimethyl-1-butyne and the like.
"Aryl" and "heteroaryl" include a 5- or 6-membered aromatic or heteroaromatic ring containing 0-3 heteroatoms selected from O, N and S; a bicyclic 'r 9- or 10-membered aromatic or heteroaromatic ring system containing 0-3 heteroatoms selected from O, N
and S; or a tricyclic 13- or 14-membered aromatic or heteroaromatic ring system containing 0-3 heteroatoms . WO 97/19679 PCT/US96/19053 selected from 0, N and S; each of which rings is optionally substituted with 1-3 lower alkyl, substituted alkyl, substituted alkynyl, =O, -NO2, halogen, hydroxy, alkoxy, -OCH(COOH)2, cyano, -NR4R' (wherein R' is independently H, lower alkyl or cycloalky, and -R°R4 may be fused to form a cyclic ring with N), acylamino, phenyl, benzyl, phenoxy, benzyloxy, heteroaryl or heteroaryloxy; each of said phenyl, benzyl, phenoxy, benzyloxy, heteroaryl and heteroaryloxy is optionally substituted with 1-3 substituents selected from lower alkyl, alkenyl, alkynyl, halogen, hydroxy, alkoxy, cyano, phenyl, benzyl, benzyloxy, caboxamido, heteroaryl, heteroaryloxy, -NOz and --NR4R4. The aromatic 6- to 14-membered carbocyclic rings include, e.g., benzene, naphthalene, indane, tetralin and fluorene, and the 5- to 10-membered aromatic heterocyclic rings include, e.g., imidazole, pyridine, indole, thiophene, benzopyranone, thiazole, furan, benzimidazole, quinoline, isoquinoline, quinoxaline, pyrimidine, pyrazine, tetrazole and pyrazole.
"Alkoxy" refers to groups of from 1 to 8 carbon atoms of straight, branched or cyclic configuration and combinations thereof. Examples include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy and the like.
"Acylamino" refers to groups of from 1 to 8 carbon atoms of a straight, branched or cyclic configuration and combinations thereof. Examples include acetylamino, butylamino, cyclohexylamino and the like.
"Halogen" includes F, C1, Br and I.
"Arylalkyl" refers to an alkyl residue attached to an aryl ring. Examples include, e.g., benzyl, phenethyl and the like.
"Heteroarylalkyl" refers to an alkyl residue attached to a heteroaryl ring. Examples include, e.g., pyridinylmethyl, pyrimidinylethyl and the like.
"Substituted" alkyl, cycloalkyl, heterocycloalkyl, alkenyl or alkynyl refers to alkyl, cycloalkyl, heterocycloalkyl, alkenyl or alkynyl wherein up to three H atoms on each C atom therein are replaced with halogen, hydroxy, loweralkoxy,' carboxy, caboalkoxy, carboxamido, cyano, carbonyl, -NOz, NRSRS (wherein RS is H, alkyl or arylalkyl) , alkylthio, sulfoxide, sulfone, acylamino, amidino, phenyl, benzyl, heteroaryl, phenoxy, benzyloxy, heteroaryloxy and substituted phenyl, benzyl, heteroaryl, phenoxy, benzyloxy or heteroaryloxy.
Brief Descrit~tion of the Drawings These and other objects, features and advantages .
of the invention will be evident from the following detailed description when read in conjunction with the accompanying drawings in which:
Figure 1 is a graph of optical density from fluorescence spectroscopy, measured as "ILIGV", per cell for four test groups of endothelial cells, showing the effect of apocynin on high-LDL induction of endothelial cell peroxide production;
Figure 2 is a graph of fluorescence per 105 cells for four test groups of endothelial cells, showing the effect of apocynin on high-LDL induction of endothelial cell endocytosis;
Figure 3 is a graph of optical density from fluorescence spectroscopy, measured as "ILIGV", per cell for four test groups of endothelial cells, showing the effect of apocynin on arachidonic acid induction of endothelial cell peroxide production;
Figure 4 is a printed reproduction of a photomicrograph of a section of abdominal aorta from a rabbit fed a high cholesterol diet;
Figure 5 is a printed reproduction of a photomicrograph of a section of abdominal aorta from a rabbit fed a high cholesterol diet and also given apocynin according to the invention;
Figure 6 is a bar graph showing the percent increase in H202 production (i.e. elevation of oxidase activity) for each of 22 patients with atherosclerosis compared to a paired control;
Figure 7 is a printed reproduction of a Western-blot of the cytosolic and membrane fractions from control endothelial cells, PMA-exposed endothelial cells and PMA-exposed endothelial cells treated with 100 ~.g/ml apocynin showing the absence of p47 ~phoX~ in the membrane fraction; and Figure 8 is a graph showing OZ- generation by whole cell endothelial cell sonicate in response to arachidonic acid, in the presence and absence of apocynin and purified apocynin dimer.
Detailed Description of the Invention The present invention provides a method for preventing and treating atherosclerosis and diseases related thereto, conditions associated with increased endothelial permeability. According to the invention, the administration of an NADPH oxidase inhibitor, such as apocynin, inhibits NADPH oxidase activation in endothelial cells. The activation of NADPH oxidase is the major cellular source of the oxidative-burst (an intensified generation of reactive oxygen species), which is associated with serum LDL levels that are known to be atherogen~ic.
The oxidative burst modulates heightened endocytosis and endothelial hyperpermeability.
The present invention additionally provides a diagnostic method for predicting the risk of atherosclerosis-related diseases by measuring NADPH
oxidase activity. Individuals with a clinically documented history of atherosclerotic-related diseases, or strong family history thereof, have higher NADPH oxidase activity than people without any medical or family history of the diseases.
A preferred NADPH oxidase inhibitor according to a method of the present invention is apocynin.
Apocynin is an orthomethoxy-substituted catechol that acts to block NADPH oxidase complex assembly by inhibiting the translocation of the p47~phoX~ cytosolic oxidase subunit to the membrane fraction. Studies 'r were performed in which EC were exposed to 10 nM PMA
in the presence and absence of 100 ug/ml apocynin for -15 minutes. Subsequently, EC cytosolic and membrane fractions were isolated. Western-blot analysis of the fractions was performed using the monoclonal antibody against p47~p,,ox] . Figure 7 reveals the absence of the cytosolic subunit p47~phox~ in the membrane fraction of EC treated with apocynin.
While a preferred NADPH oxidase inhibitor in the present invention is apocynin, the method of the invention is not limited to apocynin, and a variety of other chemicals known to inhibit NADPH oxidase in endothelial cells may be used, as will be obvious to those skilled in the art. In the case of apocynin, the intact molecule (the ortho-methoxy phenol.) appears to be effective as an inhibitor, and in~' addition, a dimer arising from metabolic oxidation is also highly effective and indeed may be the active species. Thus, compounds having an electron distribution similar to that in the dimer are effective inhibitors of NADPH oxidase and are contemplated within the invention. Examples of other types of NADPH oxidase inhibitors that may be useful include, but are not limited to, isoprenylation inhibitors such as lovastatin and compactin (see U.S.
patent 5,224,916), benzofuranyl- and benzothenylthio-alkane carboxylates (see EP application 551,662), and cytochrome bsse fragments and their analogs (see PCT
application WO 91/17763).
While it is believed that many of the known NADPH oxidase inhibitors act by interfering with the assembly of the active complex, the term NADPH
oxidase inhibitor, as used herein, is not intended to be restricted as to mechanism. Any substance that inhibits the NADPH oxidase-catalyzed generation of reactive oxygen species is encompassed by the term "NADPH oxidase inhibitor". The claimed method for treating atherosclerosis by NADPH oxidase inhibitors can be distinguished from the known methods for S
treating atherosclerosis (although the mechanism was previously unknown) employing compounds that happen also to be NADPH inhibitors. The claimed method can employ doses of known inhibitors (e. g. lovastatin) that would be therapeutically ineffective to reduce LDL-cholesterol, i.e. that produce a less than 100 lowering of serum LDL-cholesterol.
Alternatively, the claimed method employs inhibitors that are targeted to the NADPH oxidase complex in that they have a lower ICso vs human~NADPH
oxidase than vs human HMG-CaA reductase. For the purpose of the present invention, the ICSO is defined, according to standard practice, as the concentration of inhibitor required to inhibit the enzyme in question by 50%. The ICSO vs human NADPH oxidase is measured as described in US patent 5,244,916 column 11-12; the ICso vs human HMG-CoA reductase is measured as described by Edwards et al. [J. Lipid Res. 20, 40-46 (1979)]. A brief description of the HMG-CoA
reductase measurement is as follows:
A fragment of human liver is homogenized at 4° C
in 25 mL of buffer A (0.1 M sucrose, 0.05 M KC1, 0.04 M potassium phosphate and 0.03 M potassium EDTA; pH
7.2) and the microsomes are prepared as described by Edwards and Gould [J. Biol. Chem. 247, 1520-1524 (1972)]. The microsomes are resuspended in buffer A
to a concentration of approximately 82 mg protein/mL, solid DTT is added to a final concentration of l0 mM
and the microsomes are homogenized. Three mL
aliquots of the microsome suspension are frozen in glass tubes at a rate of 6-8° C per min as described by Heller and Gould [Biochem. Biophys. Res. Comm. 50, 859-865 (1973)], and stored at -20° C far up to two months.
For optimal solubilization of the reductase, the frozen microsomes are allowed to thaw at room temperature before addition of an equal volume of 50%
glycerol in buffer B (buffer A plus 10 mM DTT) preheated to 37° C. The suspension is rehomogenized and then incubated at 37° C for 60 minutes. The suspension-is diluted threefold with buffer B
preheated to 37° C to a final glycerol concentration of 8.3%, rehomogenized and centrifuged at 100,000 g for 60 minutes at 25° C-. The supernatant, containing solubilized HMG-CoA reductase, is removed and used immediately.
The activity of the solubilized HMG-CoA
reductase is determined at 37° C in a total volume of 0.5 mL using a spectrophotometer. The cell path length is 1.0 cm. The rate of oxidation of NADPH is initially determined in the absence of HMG-CoA and this blank value, if any, is subtracted from the rate obtained with both substrates.
Maximum activity is obtained by assaying the enzyme in buffer C (0.2 M KC1, 0.16 M potassium phosphate, 0.004 MEDTA, and 0.01 MDTT, pH 6.8) together with 0.2 mM NADPH and 0.1 mM RS-HMG-CoA.
One unit of enzyme activity is defined as the amount required to oxidize 2 nmol NADPH per minute. Hence, one unit is equivalent to the synthesis of 1 nmol mevalonate per minute.
Inhibition is measured in buffer C. The results are expressed as the 50% inhibitory concentration (ICSo) for the test substance. Six to ten test substance concentrations, separated by approximately 1/2 log, are tested in duplicate. The test substances are dissolved in buffer C for addition to the incubations. The ICSa is calculated by linear interpolation.
A class of inhibitors that inhibits NADPH
oxidase but does not block isoprenylation can be distinguished by the fact that they effect .
statistically equivalent inhibition of human NADPH
oxidase in the presence and absence of mevalonate (see US patent 5;244,916, column 14, line 60 to column 15, line 30).
In Vitro Apocynin Experiments Experiments were performed in vitro using a high LDL endothelial cell tissue culture system.
Endothelial cells were isolated from human umbilical -.' cord veins and placed in experimental wells to which LDL media were added. The tissue culture components and chemicals are commercially available and were obtained from Sigma, Worthington, and Gibco. LDL was isolated from human blood plasma. Apocynin is available from Carl Roth GmbH (Germany).
Studies were conducted using apocynin to block NADPH oxidase activation and thereby prevent _ heightened endocytosis. Apocynin interferes with the assembly of a functional NADPH oxidase enzyme ;
complex. For apocynin studies, EC were incubated with 240 mg/dL LDL cholesterol in the presence and absence of 100 ~.g/mL apocynin. As shown in figures 1 and 2, apocynin effectively inhibits (1) the induction of HzOz production and (2) endocytosis alterations associated with high concentrations of LDL.
As mentioned above, arachidonic acid activates EC NADPH oxidase directly, by inducing EC Hz02 generation; exposure to arachidonic acid promotes heightened EC endocytosis.
l0 Further support that the arachidonic .
acid-induced oxidative burst results from NADPH
oxidase activation is provided from the results of the following test in which apocynin was used to block NADPH oxidase activation. EC were incubated with 10 ~M arachidonic acid in the presence and absence of 100 ~.g/mL apocynin. Figure 3 shows that apocynin markedly reduces arachidonic acid-induced EC
H202 generation.
It has been demonstrated that there is a lag time of approximately two minutes before apocynin acts to inhibit NADPH oxidase activity. This delay results from the time required for apocynin to be metabolized to an active product in a chemical reaction involving ROS and peroxidase. Following this delay in effect, cellular ROS production is nearly completely inhibited.
The active metabolite of apocynin has been identified as a dimer possessing a quinone-like structure which arises from metabolic oxidation.
Studies were performed to examine ROS generation by whole cell EC sonicate, in response to arachidonic acid, in the presence and absence of the purified apocynin dimer. As seen in Figure 8, there was no ;
lag time for the nearly complete inhibition of ROS
generation in the presence of the purified apocynin dimer.
DIMERIZATION OF APOCYNIN
~~ H i w_ H
H O_[H3 ti ~ 0 H f_H~
H H i i ~. n ~ i i :i ~H <~ ~ ~ -_ sH~.. P=1'.:~;'ir_Id5= ~ ~.~~r H
r ~JCH_, Synthesis and Isolation of Apocvnin Dimer I. Synthesis A 0.02 mg/ml aqueous solution of apocynin is prepared by dissolving 10 mg apocynin volumetrically in 500 mL distilled H20. The final molarity of the solution is 1.2 x 10-4 M. A 3% H2O2 (m/m) solution is ~-prepared by diluting 1 mL of 30% H202 (m/m, 9.8 M) to 10 mL volumetrically with distilled HZO. The final molarity of the solution is 0.98 M. A 0.1 mg/mL
solution of horseradish peroxidase (HRP) is prepared by dissolving 5 mg of solid HRP in 50 mL distilled HZO
volumetrically.
100 mL of 0.02 mg/mL apocynin solution is combined with 100 uL (delivered via micropipette) of 0.1 mg/mL HRP solution in a clean, dried 250 mL
erlenmeyer flask. A magnetic stir bar is added and the solution is stirred gently. The reaction is initiated by the addition of 24 ~.L (delivered via micropipette) of the 3% Hz02 solution. After 10 seconds, the reaction mixture is quenched by the --addition of 1.5 mL of 0.1 M NaZS203. The solution is then allowed to stir vigorously for 2 minutes, at the end of which the pH of the solution is reduced to 3 to 4 by the addition of 5 drops 3 M HZS04 The quenched reaction mixture is then divided into two 50 mL portions. Each portion is extracted twice with diethyl ether (2 x 15 mL) and the ether layers are combined. The combined ether extracts are dried for .l0 minutes over a minimal amount of anhydrous MgS09, and then gravity filtered. The, ether is removed by rotary evaporation, and the resulting product, primarily a mixture of apocynin and apocynin dimer, is dissolved in CDC13 for analysis by 1H-NMR
Spectroscopy.
II. Isolation After analysis by 1H-NMR, CDC13 is removed by rotary evaporation, and the crude product mixture is dissolved in a minimal volume of HPLC Grade methanol (<1 mL). If suspended particles exist, a nylon membrane syringe filter is used to filter the solution prior to injection onto the HPLC column. To isolate the dimer, reverse phase (C18) HPLC equipped with a W detector is employed in a preparatory manner. The mobile phase is 50:50 methanol: acetate buffer (pH=4) and a 260 nm wavelength is used for detection.
Methanol is removed from the collected preparatory solution containing the dimer (10 to 20 mL) by rotary evaporation (approximately 1 hour).
WO 97/19677 PC'T/US95/15587 A solid phase extraction filter cartridge (Alltech C18 500 mg - 3 mL) is then prepared by pulling 10 mL HPLC Grade methanol, followed by 10 mL
distilled H20 through the filter. The stripped preparatory solution is passed through the filter, followed by a 4 mL distilled Hz0 rinse. The filter is allowed to dry for approximately 10 minutes, then HPLC Grade methanol aliquots are pushed through the column and collected (5 x 5 mL). The methanol is removed by rotary evaporation, and the isolated dimer , is dissolved in 3 mL CDC13. The dimer is then analyzed by 1H-NMR spectroscopy. ~ .
REDOX REACTION FOR APOCYNIN DIMER
H U H CH3 H \ U H CH3 CH3 ~ p ~,~,~ i dat i on] CH3 ~ ~ ( 0 0 H 0 H \
OH~H ( r'aduct i on] ~ O~H
While applicant does not wish to be limited by the hypothesis, it appears that apocynin may be a metabolic precursor of the species that actively inhibits NADPH oxidase.
Additional studies were conducted to provide further insight into the mechanism of NADPH oxidase activation. The cellular enzyme, phospholipase AZ
(PLAZ) hydrolyses membrane phospholipids releasing arachidonic acid intracellularly. PLA2 inhibition by its antagonist, p-bromophenacyl bromide (BPB).
suppresses the rise in cytosolic free arachidonic acid and limits this secondary messenger for NADPH
oxidase activation. Thus, PLAZ inhibition blocks LDL-EC NADPH oxidase activation. In these studies, VlfO 97/19679 PCT/US96/19053 EC were exposed to 240 mg/dL LDL-cholesterol with and without IO ~.M BPB. BPB markedly diminished LDL-EC
reactive oxygen species production.
PLAz is a Caz'-dependent enzyme . Likewise, Ca2' is required for NADPH oxidase activation in intact cells. PLAZ-mediated arachidonic acid release parallels extracellular Caz' concentration. Studies were conducted to determine whethcer LDL-EC have increased cellular Cap' influx. In these studies, EC
were incubated with increasing LDL levels (30 to 240 mg/dL cholesterol), and cellular Caz' influx was measured employing a "SCaz' uptake assay as described by Lewis et al. [J. C1'in. Invest., 82, 2045-2055 (1988)]. It was found that LDL-EC promote a dose-dependent rise in cellular Ca2' influx. LDL may induce Ca2' influx by EC exposure to H20z, causing cellular permeabilization to Cap' and resulting in an intracellular calcium elevation.
The above studies in vitro demonstrated that atherogenic LDL levels induce heightened EC
endocytosis and that reactive oxygen species, produced predominantly by NADPH oxidase, modulate heightened EC endocytosis. To restate, while not intending to be held to any particular theory, one may hypothesize, based on the above studies .in vitro, that reactive oxygen species, generated by activated EC NADPH oxidase, modulate hypercholesterolemia-induced vascular hyperpermeability via heightened EC
endocytosis.
High LDL exposure initially activates phospholipase AZ activity releasing arachidonic acid from phospholipids. Cytoplasmic free arachidonic acid, at a threshold level, converts an inactive genetic variant of NADPH oxidase to its active form.
This genetic NADPH oxidase variant generates increased amounts of reactive oxygen species which _ perturb the cell membrane and enhance PLAZ activation.
PLAZ activation is further enhanced by reactive oxygen species-mediated cellular Caz' influx. Arachidonic acid released from membrane phospholipids markedly escalates NADPH oxidase enzyme complex recruitment and assembly. The multiple, membrane-bound, assembled-enzyme complexes. generate excessive quantities of reactive oxygen species, Oz- and HzOz.
These reactive oxygen species increase membrane' fluidity and decrease the energy of activation for endocytosis. The combination of these LDL-induced cellular events result in heightened EC endocytosis, vascular hyperpermeability, and~increased transcellular transport via transcytosis.
Thus, inhibition of NADPH oxidase activation with apocynin, for example, prevents heightened EC
endocytosis and reduces vascular hyperpermeability.
While not wishing to be restricted to a particular theory, it is possible that the inhibition of NADPH oxidase by the apocynin dimer may involve the disruption of the electron transport chain in the NADPH oxidase activation process. NADPH Oxidase activation requires the coupling of electron transport function between ubiquinone (co-enzyme Q) and cytochrome b. An oxidized dimer having a lower reduction potential than ubiquinone would then block the electron transport chain. ':
In Vivo Apocynin Experiments To test the foregoing hypothesis, studies were conducted in vivo, which focused on the effect of NADPH oxidase inhibition on vascular hyperpermeability using a hypercholesterolemic rabbit model. New Zealand white male rabbits were placed on a is cholesterol diet with (n=5) and without (n=5) 200 ~cg/mL apocynin added to their drinking water.
After one month from commencement of feed, animals were infused with horseradish peroxidase (HRP) as a permeability tracer one minute prior to sacrifice.
The aortas were excised, opened, and pinned to~a dissecting tray. Gross visual inspection revealed that aortas of 1% cholesterol-fed rabbits without apocynin treatment had typical, diffuse early.
atherosclerotic lesions. In contrast, an absence of lesions was noted in the aortas of hypercholesterolemic rabbits treated with apocynin.
Subsequently, aortas were exposed to diaminobenzidine and H20a, and a brown reaction precipitate developed at sites of high HRP concentrations. Aortas of hypercholesterolemic rabbits without apocynin treatment had marked, diffuse areas of high HRP
concentrations. However, aortas of hypercholesterolemic animals treated with apocynin consistently showed few HRP-positive areas, a pattern similar to that seen in rabbits fed standard rabbit chow. The total serum cholesterol levels of hypercholesterolemic rabbits with and without = 30 apocynin treatment were comparable.
A three month study was also carried out using ten New Zealand white male rabbits fed a 1%
cholesterol diet with 30 ~,g/mL (n=2), 200 ~.g/mL
(n=2), 400 ~g/mL (n=2), 800 ug/mL (n=2), and without (n=2) apocynin added to their drinking water. After three months, the animals were sacrificed, and their aortas were examined as before. Visual inspection revealed that aortas of 1% cholesterol-fed rabbits without apocynin treatment had in the range of 60% of aortic surface area covered with atherosclerotic plaque. In contrast, a dose-dependent diminution of lesions was noted in the aortas of hypercholesterolemic rabbits treated with apocynin.
In animals treated with greater than 200 ~,g/mL of apocynin, aortic surface covered with plaque. was reduced to less than 8%. The total serum cholesterol levels of hypercholesterolemic rabbits with and without apocynin treatment were comparable at about 1000 mg/dL.
Morphologic examination of aortic endothelium from the one and three-month rabbits was performed.
Random tissue samples were taken from the thoracic and abdominal aortas of hypercholesterolemic rabbits and hypercholesterolemic rabbits treated with apocynin. Tissue samples were thin sectioned and processed for microscopy. Examination of electron and light micrographs from hypercholesterolemic rabbits without apocynin treatment revealed frequent and diffuse vascular changes characteristic of atherosclerotic disease. Figure 4 is a representative light micrograph. In contrast, examination of multiple tissue samples from hypercholesterolemic rabbits with apocynin treatment '-revealed little evidence for vascular changes.
Figure 5 is a representative light micrograph. The effect of NADPH oxidase inhibition on coronary artery endothelium was similarly examined. Like the abdominal aorta, the coronary artery was found to exhibit vascular changes characteristic of atherosclerotic disease, and these changes were attenuated by treatment with apocynin.
To provide experimental evidence that apocynin reduces vascular hyperpermeability by preventing heightened EC endocytosis from occurring, the number of endocytotic vesicles on EC luminal and abluminal sides from electron micrographs were counted as an approximate measure of endocytotic activity.
Electron micrographs of 50 randomly selected~cells from aortas of hypercholesterolemic rabbits treated with and without apocyriin were taken at 35,OOOX
magnification. Endocytotic vesicles were counted on luminal and abluminal cell sides. Vesicles counted included those that were forming in the plasma membrane or clearly attached to the membrane. A
significant decrease in the number of endocytotic vesicles in apocynin treated animals was observed, suggesting that apocynin acts by averting endocytosis increases.
Side Effects Rabbits treated with apocynin for a three month period demonstrated no overt signs of ill health.
Weight gain, over the three month period, for apocynin-treated rabbits was comparable to those animals without apocynin treatment.
One might have expected that apocynin might increase susceptibility to infections, since white blood cells use NADPH oxidase to generate ROS to kill bacteria. However, no increased incidence of WO 97!19679 PC'T/US96/19053 infections in the New Zealand White male rabbits was seen.
Another theoretical side effect of apocynin .
might have been thought to result from inhibition of cell 'proliferation. Certain tissues of the body, including bone marrow and gastrointestinal cells, have higher cell proliferation rates. Cell growth studies showed the dose-dependent effect of apocynin on endothelial and smooth muscle cell proliferation.
At 100 ~Cg/mL apocynin, the cell proliferation rates were minimal, however, visual inspection of the cells revealed no evidence of cell injury or death at'the apocynin concentrations-tested. Thus, at concentrations that inhibit ROS generation, apocynin is highly effective at suppressing cell proliferation.
Conclusion The above studies in vitro and in vivo indicate that the administration of NADPH oxidase inhibitors, such as apocynin, can prevent and treat diseases associated with hyperpermeability of endothelial cells, including atherosclerosis and its related diseases. In addition to the prevention of atherosclerosis, NADPH oxidase inhibitors, such as apocynin, may be useful for the prevention and treatment of the following conditions by decreasing membrane permeability and cell proliferation associated therewith: arthritis, cancer, sepsis; ..
post-stroke and post-MI tissue swelling and reperfusion injury; adult respiratory distress syndrome CARDS); growth malignancies; post-transplant vascular changes; vasculitides; asthma and diabetes mellitus.
The optimal dose of the NADPH oxidase inhibitor, such as apocynin, to be used in humans will vary depending upon the severity and nature of the condition to be treated, the route of administration, the age, weight, and sex of the patient, as well as on any other medications being taken by the particular patient or the existence of any complicating significant medical conditions of the patient being treated. The dose and perhaps.the dose frequency will also vary according to the response of the individual patient.' In general, the total daily dose range for apocynin for the conditions described herein is from about 10 mg/kg/day to about 45 mg/kg/day; for the average human, the total dose is about 500 mg to about 3000 mg daily, preferably in divided doses. In managing the patient, the therapy should be initiated at a lower dose, perhaps at about 200 mg to about 500 mg, and increased up to about 1000 mg depending on the patient's global response.
It is further recommended that patients over 65 years and those with impaired renal or hepatic function initially receive low doses and that they be titrated based on individual responses) and blood level(s).
It may be necessary to use dosages outside these ranges in some cases, as will be apparent to those skilled in the art. Further, it is noted that the clinician or treating physician will know how and when to interrupt, adjust, or terminate therapy in conjunction with individual patient response. The terms "a therapeutically effective amount" and "an amount sufficient to prevent" a condition are encompassed by the above-described dosage amounts and dose frequency schedule.
z Any suitable route of administration may be employed for providing the patient with an effective dosage of apocynin. For example, oral, rectal, parenteral (subcutaneous, intramuscular, intravenous), transdermal, aerosol and like forms of administration may be employed. Oral dosage is preferred.
Studies on Prediction of Risk of Atherosclerosis If a heightened endocytosis mechanism predominantly involves an endothelial cell defect rather than an atherogenic LDL type, one could explain why certain people with plasma LDL levels commonly associated with atherosclerosis do not develop atherosclerotic-related diseases. The EC
defect hypothesis would also suggest that atherosclerotic patients should exhibit in common some elevation in NADPH oxidase activity.
To test the hypothesis, 92 high LDL-EC
endocytosis experiments with cell isolates from 92 separate human umbilical cords were conducted in vitro. In addition, LDL preparations, isolated weekly from different human sources, were generally used on EC isolates derived from two or more human sources, thus allowing for analysis of LDL's effect.
Endothelial cells from the same cord all had similar ',-endocytotic activity with exposure to high LDL
levels. In contrast, EC from different cord sources .
responded differently, ranging from no endocytosis change to 200-300% increases in endocytotic activity over control cells.
In 52% of EC isolates tested, high LDL exposure induced a wide variation in degree of response ranging from 5 to 300% endocytosis increases. This observation in vitro correlates with epidemiologic studies that indicate that mortality from atherosclerotic-related diseases occurs in approximately 50% of the population.
If, contrary to the EC hypothesis, an -atherogenic LDL type exists, one would expect that EC
isolates from multiple human sources would all have similar responses when exposed to the same LDL
preparation. EC isolates tested were classified as no response (0 to 5% endocytosis increase) or response (5 to 300% endocytosis increase) and analyzed. Results showed that in only 53% of experiments did all EC isolates, exposed to the same LDL preparation, either respond or have no response.
The importance of this finding is that it suggests the likelihood that the heightened endocytosis mechanism predominantly involves an EC defect rather than an atherogenic LDL type. Thus, high levels of LDL's appear to activate the heightened endocytosis mechanism.
This finding explains why certain people with plasma LDL levels commonly associated with atherosclerosis do not develop atherosclerotic-related diseases and leads to the inventive method for predicting an individual's risk of atherosclerosis. By identifying a patient having elevated NADPH oxidase activity' one can predict an increased risk of atherosclerosis. Administration of apocynin or other NADPH oxidase inhibitor can then be recommended for preventing atherosclerosis and its related diseases to those identified patients.
If genetic variants of NADPH oxidase or enzymes involved in its activation exist in the human population, and some of these variants generate excessive amounts of reactive oxygen species, this should correlate with clinical atherosclerosis.
Human studies were therefore undertaken. In theses studies, the polymorphonuclear leukocyte (PMN) NADPH
oxidase activity in individuals having a history of clinically documented atherosclerosis-related diseases or strong family history thereof was compared with that of individuals having no medical or family history of the diseases. Volunteers provided a medical and family history of atherosclerotic related diseases and a venous blood sample. PMN NADPH oxidase activity was measured by flow cytometry with a fluorescent probe, using 2,7-dichlorofluorescin diacetate as indicator. NADPH
oxidase activity was determined by taking fluorescent measurements from the PMN gated window. For these studies, 22 individuals with either clinically documented medical or family history of atherosclerotic-related diseases (experimental) were compared to 11 individuals (controls) with no clinical evidence of or family history of the diseases.
The results, as illustrated in Figure 6, reveal that the 22 experimental human subjects had significantly increased NADPH oxidase activity over their paired controls (Probability for significance 'vV0 97/19679 PCT/US96/19053 of test: P < 0.07). The findings suggest that genetic variants of NADPH oxidase (or enzymes involved in its activation) exist, and that people with these genetic variants are at higher risk of atherosclerotic-related diseases.
While the invention has been particularly shown and described with reference to preferred embodiments thereof, it will be understood by those skilled in the art that other changes in form and details may be made therein without departing from the spirit and scope of the invention.
Claims (4)
1. A method for predicting risk of a human patient to a disease that results from endothelial hyperpermeability said method comprising:
a. measuring NADPH oxidase activity in said patient; and b. identifying a patient having NADPH oxidase activity more than 10% above the range found in paired controls.
a. measuring NADPH oxidase activity in said patient; and b. identifying a patient having NADPH oxidase activity more than 10% above the range found in paired controls.
2. The method according to claim 1 wherein said disease that results from endothelial hyperpermeability is atherosclerosis.
3. The method according to claim 1 wherein NADPH
oxidase activity is measured in polymorphonuclear leukocytes obtained from the blood of said patient.
oxidase activity is measured in polymorphonuclear leukocytes obtained from the blood of said patient.
4. The method according to claim 3 wherein said measuring is accompanied by flow cytometry.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/562,767 | 1995-11-27 | ||
US08/562,767 US5763496A (en) | 1995-11-27 | 1995-11-27 | Prevention of atherosclerosis using NADPH oxidase inhibitors |
CA002238098A CA2238098C (en) | 1995-11-27 | 1996-11-27 | Use of nadph oxidase inhibitors for the manufacture of a medicament for prevention of atherosclerosis |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002238098A Division CA2238098C (en) | 1995-11-27 | 1996-11-27 | Use of nadph oxidase inhibitors for the manufacture of a medicament for prevention of atherosclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2309881A1 true CA2309881A1 (en) | 1997-06-05 |
Family
ID=25680219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002309881A Abandoned CA2309881A1 (en) | 1995-11-27 | 1996-11-27 | Use of nadph oxidase inhibitors for the manufacture of a medicament for prevention of atherosclerosis |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2309881A1 (en) |
-
1996
- 1996-11-27 CA CA002309881A patent/CA2309881A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5902831A (en) | Prevention of atherosclerosis using NADPH oxidase inhibitors | |
US4708964A (en) | Lipoxygenase inhibitors | |
Yamamoto et al. | Therapeutic effects of ML-236B in primary hypercholesterolemia | |
TW552137B (en) | Pharmaceutical compositions for inhibiting oxidation of lipoproteins, scavenging free radicals and inhibiting metal ion chelation of lipoproteins | |
Soudamini et al. | Inhibition of lipid peroxidation and cholesterol levels in mice by curcumin | |
EP1244460B1 (en) | Use of dipyridinium compounds for treating a disease characterized by proliferating cells containing nitric oxide synthase | |
Cortese et al. | Podophyllotoxin as a probe for the colchicine binding site of tubulin. | |
EP0801564B1 (en) | Use of nebivolol as an anti-atherogenic | |
US4346103A (en) | Treatment for arthritis and substances for use in such treatment | |
JP4097285B2 (en) | Compositions useful in the manufacture of a medicament for the treatment of various stubborn diseases | |
KR970005180B1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING MAGNESIUM-PYRIDOXAL-5íÃ-PHOSPHATE-GLUTAMINATE FOR THE PREVENTION OF DISEASES WHICH RESULT FROM LDL-BOUND PEROXIDES | |
Fieseler et al. | Serum Lp (a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor Pravastatin: results of a 2-year investigation | |
US4845123A (en) | Reduction in vivo of the inappropriate levels of endogenous and environmental-derived compounds by sustained-release inhibitors of β-g | |
Pappu et al. | Reduction in plasma low-density lipoprotein cholesterol and urinary mevalonic acid by lovastatin in patients with heterozygous familial hypercholesterolemia | |
Kumar | Effect of simvastatin on paraoxonase 1 (PON1) activity and oxidative stress | |
KR930010581B1 (en) | Use of tenidap to inhibit activation of collagenase and to inhibit the activity of myeloperoxidase | |
Durairaj et al. | Protective effects of curcumin on bleomycin-induced changes in lung glycoproteins | |
CA2309881A1 (en) | Use of nadph oxidase inhibitors for the manufacture of a medicament for prevention of atherosclerosis | |
US5576347A (en) | Method of treating gastric ulcers | |
Gaw et al. | Fibric acid derivatives | |
WO1992003130A1 (en) | Use of aryl hydroxyurea compounds for the treatment of atherosclerosis | |
JP3153070B2 (en) | How to lower blood lipid levels | |
Fanta | Calcium-channel blockers in prophylaxis and treatment of asthma | |
Tavridou et al. | Antioxidant properties of two novel 2-biphenylmorpholine compounds (EP2306 and EP2302) in vitro and in vivo | |
Hand et al. | WY-48,252 (1, 1, 1-trifluoro-N-[3-(2-quinolinylmethoxy) phenyl] methane sulfonamide) an orally active leukotriene D4 antagonist: Pharmacological characterization in vitro and in vivo in the guinea pig |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |